<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methylphenidate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methylphenidate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methylphenidate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11797" href="/d/html/11797.html" rel="external">see "Methylphenidate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12600" href="/d/html/12600.html" rel="external">see "Methylphenidate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58227447"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">ADHD Stimulant Safety Alert</span>
<span class="collapsible-date">May 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA is requiring updates to the Boxed Warning and other sections in the prescribing information of prescription stimulants to ensure consistency across the class of medicines and address continuing concerns of misuse, abuse, substance use disorder, and overdose. The current prescribing information for some prescription stimulants does not provide up-to-date warnings about the harms of misuse and abuse, and particularly that most individuals who misuse prescription stimulants get them from other family members or peers. The FDA is adding information that patients should never share prescription stimulants with anyone, and the Boxed Warning will describe the risks of misuse, abuse, substance use disorder, and overdose consistently across all medicines in the class, as well as advise health care professionals to monitor patients closely for signs and symptoms of misuse, abuse, and substance use disorder. Information on these risks is being required in several sections of the prescribing information, including Warnings and Precautions, Drug Abuse and Dependence, Overdosage, and Patient Counseling sections; updates to existing Medication Guides are also required to help educate patients and caregivers about these risks.</p>
<p style="text-indent:0em;">Further information can be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions&amp;token=2htBI%2BZJP9KguLNT5e%2FO5JB3a3lhB47gC48SVmgo9Z800H4ddHXFGN3vhQ%2BWdW5yurFpw9BeJ%2FM6gAUY1Tt1jyGUCu7UWgLKdtpLZMlcF4ajBtdi8HzFE4w2iTIacoZKOst31pB5%2B5utMl%2FdfB4GdprCpFXm3czU9pi4wB1ZjvM%3D&amp;TOPIC_ID=9638" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5709144"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate has a high potential for abuse and dependence, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Before prescribing methylphenidate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout methylphenidate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F195295"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adhansia XR [DSC];</li>
<li>Aptensio XR;</li>
<li>Concerta;</li>
<li>Cotempla XR-ODT;</li>
<li>Daytrana;</li>
<li>Jornay PM;</li>
<li>Methylin;</li>
<li>QuilliChew ER;</li>
<li>Quillivant XR;</li>
<li>Relexxii;</li>
<li>Ritalin;</li>
<li>Ritalin LA</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867530"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Methylphenidate ER;</li>
<li>APO-Methylphenidate;</li>
<li>APO-Methylphenidate ER;</li>
<li>APO-Methylphenidate SR;</li>
<li>Biphentin;</li>
<li>Concerta;</li>
<li>Foquest;</li>
<li>PMS-Methylphenidate;</li>
<li>PMS-Methylphenidate CR;</li>
<li>Ritalin SR [DSC];</li>
<li>Ritalin [DSC];</li>
<li>SANDOZ Methylphenidate SR [DSC];</li>
<li>TEVA-Methylphenidate ER-C [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F195328"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Central Nervous System Stimulant</li></ul></div>
<div class="block doa drugH1Div" id="F195300"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Due to pharmacokinetic differences, many products are not bioequivalent and not interchangeable on a mg-per-mg basis; when available, dosing conversion information is provided.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30097390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30097390'])">Ref</a></span>)): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Short-acting immediate release:</b></i>
<i> Chewable tablets, Methylin (oral solution), and Ritalin (tablets): </i>
<b>Oral:</b> Initial: 10 to 20 mg/day in 2 divided doses before breakfast and lunch; may increase based on response and tolerability in 5 to 10 mg increments at weekly or greater intervals up to a maximum dose of 60 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31038360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31038360'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Intermediate-acting extended release</b></i>
<i>
<b>: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Metadate ER (tablets):</i>
<b>Oral:</b> Initial: 10 mg twice daily; may increase dose based on response and tolerability in 10 mg increments at weekly or greater intervals up to a maximum dose of 60 mg/day. Some experts suggest a further increase up to 100 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24526134','lexi-content-ref-Bukstein.1','lexi-content-ref-28740389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24526134','lexi-content-ref-Bukstein.1','lexi-content-ref-28740389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Ritalin SR (tablets) [Canadian product]:</i>
<b>Oral:</b> Initial: 20 mg once daily in the morning; may increase dose based on response and tolerability in 10 mg increments at weekly or greater intervals up to a maximum dose of 60 mg/day. Some experts suggest a further increase up to 100 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24526134','lexi-content-ref-Bukstein.1','lexi-content-ref-28740389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24526134','lexi-content-ref-Bukstein.1','lexi-content-ref-28740389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion from IR methylphenidate to Metadate ER or Ritalin SR [Canadian product]:</i> To substitute the intermediate-acting ER formulation for the short-acting IR formulation, the dose of the ER formulation (8-hour duration) should correspond to the total 8-hour IR dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Long-acting extended release and transdermal:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adhansia XR (capsules): </i>
<b>Oral:</b> Initial: 25 mg once daily in the morning; may increase dose based on response and tolerability in 10 to 15 mg increments at intervals of ≥5 days up to a maximum dose of 100 mg/day. Doses &gt;85 mg are associated with higher rate of side effects.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from IR methylphenidate to Adhansia XR: Discontinue previous formulation and titrate using above schedule; do not substitute on a mg-per-mg basis.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Adhansia XR has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Aptensio XR (capsules):</i>
<b>Oral:</b> Initial: 10 mg once daily in the morning; may increase dose based on response and tolerability in 10 mg increments at weekly or greater intervals up to a maximum dose of 60 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from other methylphenidate products to Aptensio XR: There are no conversion recommendations in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Biphentin [Canadian product] (capsules):</i>
<b>Oral:</b> Initial: 10 to 20 mg once daily in the morning; may increase dose based on response and tolerability in 10 mg increments at weekly or greater intervals up to a maximum dose of 80 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from IR methylphenidate to Biphentin: Use equivalent total daily dose (TDD) administered once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concerta (tablets)</i>: <b>Oral:</b> Initial: 18 to 36 mg once daily in the morning; may increase dose based on response and tolerability in increments of 18 mg at weekly or greater intervals up to a maximum dose of 72 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from IR methylphenidate and intermediate-acting ER methylphenidate (eg, Metadate ER, Ritalin SR [Canadian product]) to Concerta:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:center;">
<b>Concerta Dosing Conversion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">IR methylphenidate (current dose)</p></th>
<th align="center">
<p style="text-indent:0em;">Intermediate-acting ER methylphenidate (Metadate ER, Ritalin SR [Canadian product]) (current dose)<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Concerta initial dose</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Concerta Canadian product labeling.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">5 mg 2 to 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">18 mg once daily in the morning</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 mg 2 to 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">40 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">36 mg once daily in the morning</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 mg 2 to 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">60 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;">54 mg once daily in the morning</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 mg 2 to 3 times daily</p></td>
<td align="center">
<p style="text-indent:0em;">--</p></td>
<td align="center">
<p style="text-indent:0em;">72 mg once daily in the morning</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>Daytrana </i>
<i>transdermal patch:</i>
<b>Topical:</b> Initial: 10 mg patch once daily; apply to hip 2 hours before effect is needed and remove 9 hours after application (eg, 3 hours before bedtime); may increase dose based on response and tolerability to the next transdermal patch dosage at intervals of ≥1 week up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20410322','lexi-content-ref-20538968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20410322','lexi-content-ref-20538968'])">Ref</a></span>). Some patients may require up to 60 mg/day for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bukstein.1','lexi-content-ref-28740389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bukstein.1','lexi-content-ref-28740389'])">Ref</a></span>). Patch may be removed before 9 hours if a shorter duration of action is required or if late-day adverse effects appear, or it may be worn for up to 16 hours if extended duration of effects is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17974748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17974748'])">Ref</a></span>). Plasma concentrations usually start to decline when the patch is removed but drug absorption may continue for several hours after patch removal.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from IR methylphenidate or from Concerta (long-acting extended release) to the transdermal patch: Discontinue previous formulation and titrate using above schedule; do not substitute on a mg-per-mg basis per manufacturer's labeling. Alternatively, some clinicians support higher starting patch doses for patients converting from oral methylphenidate doses of &gt;20 mg/day. Approximate equivalent doses, with a 9-hour patch wear time, are as follows below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17974748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17974748'])">Ref</a></span>):</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:center;">
<b>Transdermal Dosing Conversion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Immediate release (mg/day)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Concerta (mg/day)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Patch size (Daytrana)</b></p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">18</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg (12.5 cm<sup>2</sup>)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">22.5</p></td>
<td align="center">
<p style="text-indent:0em;">27</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg (18.75 cm<sup>2</sup>)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">36</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg (25 cm<sup>2</sup>)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">45</p></td>
<td align="center">
<p style="text-indent:0em;">54</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg (37.5 cm<sup>2</sup>)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>Foquest [Canadian product] (capsules): </i>
<b>Oral:</b> Initial: 25 mg once daily in the morning; may increase dose based on response and tolerability at ≥5-day intervals up to a maximum dose of 100 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from IR, intermediate-acting ER, or long-acting ER methylphenidate to Foquest: Using available Foquest capsule strengths, initiate at a TDD that is close to but does not exceed the current total methylphenidate daily dose; do not substitute on a mg-per-mg basis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Jornay PM (capsules):</i>
<b>Oral:</b> Initial: 20 mg once daily in the evening between 6:30 PM and 9:30 PM (eg, 8:00 PM); may increase dose based on response and tolerability in increments of 20 mg at weekly or greater intervals up to a maximum dose of 100 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from IR methylphenidate to Jornay PM: Discontinue previous formulation and titrate using above schedule; do not substitute on a mg-per-mg basis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Methylphenidate ER capsules (eg, generic Metadate CD), QuilliChew ER (chewable tablets), Quillivant XR (oral suspension):</i>
<b>Oral:</b> Initial: 20 mg once daily in the morning; may increase dose based on response and tolerability in 10 to 20 mg increments at weekly or greater intervals up to a maximum dose of 60 mg/day. Some experts suggest a further increase up to 100 mg/day with methylphenidate ER capsule (generic Metadate CD) may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24526134','lexi-content-ref-Bukstein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24526134','lexi-content-ref-Bukstein.1'])">Ref</a></span>). <b>Note:</b> QuilliChew ER tablets are scored and may be broken in half for 10 mg and 15 mg doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion from IR, intermediate-acting ER, or long-acting ER methylphenidate to QuilliChew ER or Quillivant XR: Discontinue previous formulation and titrate using above schedule; do not substitute on a mg-per-mg basis. There are no conversion recommendations in the manufacturer's labeling for methylphenidate ER capsules (generic Metadate CD).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Relexxii (tablets):</i>
<b>Oral:</b> Initial: 18 or 36 mg once daily in the morning; may increase daily dose based on response and tolerability in increments of 18 mg at weekly intervals up to a maximum dose of 72 mg/day.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Conversion From Methylphenidate Regimens to Relexxii</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Methylphenidate (current dose)</p></th>
<th align="left">
<p style="text-indent:0em;">Relexxii initial dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">5 mg 2 to 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;">18 mg once daily in the morning</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 mg 2 to 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;">36 mg once daily in the morning</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 mg 2 to 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;">54 mg once daily in the morning</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 mg 2 to 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;">72 mg once daily in the morning</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee7d0378-a538-4532-a6b0-9166a736c507">Fatigue, severe, cancer related or in palliative care setting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fatigue, severe, cancer related or in palliative care setting (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (Methylin, Ritalin):</i>
<b>Oral:</b> Initial: 5 mg once daily or 5 mg twice daily before breakfast and lunch; may increase dose based on response and tolerability in increments of 5 to 10 mg every 3 days up to a maximum dose of 40 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bruera.1','lexi-content-ref-22208450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bruera.1','lexi-content-ref-22208450'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed9a0631-d703-4628-b94f-8df73c14ff23">Major depressive disorder in medically ill, palliative care, terminal illness, or elderly patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) in medically ill, palliative care, terminal illness, or elderly patients (monotherapy or adjunctive therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use as monotherapy only in patients with anticipated short remaining lifetime that would preclude onset of effect of an antidepressant; otherwise use as adjunct to antidepressant.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (Methylin, Ritalin): </i>
<b>Oral:</b> Initial: 2.5 to 5 mg once daily before breakfast or twice daily before breakfast and lunch; may increase dose based on response and tolerability in increments of 2.5 to 5 mg every 1 to 4 days up to 40 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19281939','lexi-content-ref-22208450','lexi-content-ref-16473984','lexi-content-ref-25677354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19281939','lexi-content-ref-22208450','lexi-content-ref-16473984','lexi-content-ref-25677354'])">Ref</a></span>). Some experts suggest a further increase up to 60 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roy.1'])">Ref</a></span>). <i>Do</i>
<b>
<i> not </i></b>
<i>use sustained-release product.</i></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy (alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16987156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16987156'])">Ref</a></span>)):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (Methylin, Ritalin):</i>
<b>Oral:</b> Initial: 10 mg twice daily before breakfast and lunch; may increase dose based on response and tolerability in increments of 5 to 10 mg at intervals of ≥1 week up to a maximum dose of 60 mg/day in 2 to 3 divided doses with the last dose given no later than about 3:00 PM (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3704451','lexi-content-ref-Scammell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3704451','lexi-content-ref-Scammell.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermediate-acting extended release (Metadate ER, Ritalin SR [Canadian product]): </i>
<b>Oral:</b> Substitute the intermediate-acting ER formulation in place of the short-acting immediate release when the total 8-hour IR dose corresponds to the ER tablet strength (usually dosed as 20 mg twice daily; duration of action: ~8 hours); maximum: 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Scammell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Scammell.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991283"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: Oral, Transdermal:</b> No dosage adjustment necessary for any degree of kidney impairment; undergoes extensive metabolism to a metabolite with little to no known pharmacologic or toxic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent hemodialysis (thrice weekly):</b>
<b>Oral, Transdermal:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: Oral, Transdermal:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: Oral, Transdermal:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): Oral, Transdermal:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988597"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F195301"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F195313"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12600" href="/d/html/12600.html" rel="external">see "Methylphenidate: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b> Methylphenidate is recommended as first-line therapy for children and adolescents; dosage should be individualized; a discontinuation trial after 6 months of therapy is also recommended to reassess underlying psychopathology (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-22003063','lexi-content-ref-30097390','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-22003063','lexi-content-ref-30097390','lexi-content-ref-NICE.1'])">Ref</a></span>). <b>Note:</b> Discontinue medication if no improvement is seen after appropriate dosage adjustment over a 1-month period of time.</p>
<p style="text-indent:-2em;margin-left:4em;">Due to pharmacokinetic differences, many products are not bioequivalent and not interchangeable on a mg per mg basis; when available, dosing conversion information is provided. Presented maximum doses are primarily based on manufacturer's labeling from clinical trials, however, higher maximum doses from guidelines are also included; dose titration should be optimized for efficacy and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22003063','lexi-content-ref-30097390','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22003063','lexi-content-ref-30097390','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate-release products (eg, Methylin, Ritalin):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to 5 years, moderate to severe dysfunction: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31967914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31967914'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> AAP considers first-line agent in this patient population if pharmacological treatment deemed necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22003063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22003063'])">Ref</a></span>); the AACAP Preschool Psychopharmacology Working Group recommends a discontinuation trial after 6 months of treatment in preschoolers to reassess underlying psychopathology (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18030077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18030077'])">Ref</a></span>). Response may be variable and less robust than that observed in older pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18844482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18844482'])">Ref</a></span>); of note, response to methylphenidate was predicted by the number of comorbidities (eg, no or 1 comorbidity predicted a large treatment response [similar to school-aged children] vs ≥3 comorbidities predicted no treatment response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18844482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18844482'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 2.5 mg twice daily, may gradually titrate to 7.5 mg 2 or 3 times daily over 2 to 4 weeks; others have used a rapid titration to 7.5 mg 3 times daily within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18844482','lexi-content-ref-17023869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18844482','lexi-content-ref-17023869'])">Ref</a></span>); a small percentage of preschool children may benefit from 1.25 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18844482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18844482'])">Ref</a></span>). In the largest trial, a multicenter, randomized, placebo-controlled, crossover study of 165 preschool children (age range: 3 to 5.5 years) treated with methylphenidate 3.75 to 30 mg/day in 3 divided doses, statistically and clinically significant improvements in ADHD scores were reported with doses of 2.5 mg, 5 mg, and 7.5 mg 3 times daily. In some patients (n=7 [4%]), dose titration to 10 mg 3 times daily was necessary; the mean effective total daily dose: 14.2 ± 8.1 mg/<b>day</b>. Although ADHD scores were statistically and clinically improved with methylphenidate use, the effect size was smaller with this younger patient population than that seen in school-age children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17023869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17023869'])">Ref</a></span>). The 10-month continuation phase trial reported continued or stable clinical improvement at a mean dose of 19.98 mg/day at month 10 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17979580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17979580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: Initial: 2.5 to 5 mg twice daily administered before breakfast and lunch; increase by 5 to 10 mg/day at weekly intervals; some patients may require 3 doses/day (eg, additional dose after school); usual maximum daily dose: 60 mg<b>/day,</b> not to exceed 2 mg/kg/<b>day</b>; however, some patients weighing &gt;50 kg may require and tolerate daily doses up to 100 mg/<b>day </b>with frequent monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Extended-release, sustained-release, and long-acting products:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Adhansia XR: Children ≥6 years and Adolescents: Initial: 25 mg once daily in the morning; may titrate in 10 to 15 mg increments at ≥5-day intervals; maximum daily dose: 85 mg/<b>day</b>; doses ≥70 mg/day, although efficacious, were associated with disproportionate increase in adverse reaction; monitor tolerability closely in these patients. To convert from other methylphenidate products, discontinue that treatment and begin Adhansia XR with titration schedule previously described. <b>Note:</b> Adhansia XR has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:6em;">Aptensio XR: Children ≥6 years and Adolescents: Initial: 10 mg once daily in the morning; may titrate in 10 mg increments at weekly intervals; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Concerta: Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Methylphenidate-naive patients:</i> Initial: 18 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients currently using immediate-release methylphenidate:</i> Initial dose: Dosing based on current regimen and clinical judgment; suggested dosing listed below, monitor closely with any therapy change:</p>
<p style="text-indent:-2em;margin-left:10em;">Switching from methylphenidate immediate release 5 mg 2 to 3 times daily: Concerta 18 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Switching from methylphenidate immediate release 10 mg 2 to 3 times daily: Concerta 36 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Switching from methylphenidate immediate release 15 mg 2 to 3 times daily: Concerta 54 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Switching from methylphenidate immediate release 20 mg 2 to 3 times daily: Concerta 72 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment:</i> May increase by Concerta 18 mg/day increments at weekly intervals to effect not to exceed the following maximum daily dose for age. <b>Note:</b> A dosage strength of 27 mg is available for situations in which a dosage between 18 and 36 mg is desired.</p>
<p style="text-indent:-2em;margin-left:10em;">Maximum daily dose of Concerta:</p>
<p style="text-indent:-2em;margin-left:12em;">Children 6 to 12 years: Usual maximum daily dose: 54 mg/<b>day</b>; however, some patients may require and tolerate daily doses up to 108 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Adolescents: Usual maximum daily dose: 72 mg/<b>day</b>; however, some patients may require and tolerate daily doses up to 108 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cotempla XR-ODT: Children ≥6 years and Adolescents ≤17 years: Initial: 17.3 mg once daily in the morning; may titrate in 8.6 or 17.3 mg increments at weekly intervals; maximum daily dose: 51.8 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Jornay PM: Children ≥6 years and Adolescents: Initial: 20 mg once daily in the evening between 6:30 and 9:30 PM (eg, 8:00 PM); may increase in increments of 20 mg/day at weekly intervals; maximum daily dose: 100 mg/<b>day</b>. <b>Note:</b> If converting from another methylphenidate formulation, discontinue previous formulation and titrate Jornay PM using above schedule; do not substitute on a milligram-per-milligram basis.</p>
<p style="text-indent:-2em;margin-left:6em;">Metadate ER, Ritalin-SR: Children ≥6 years and Adolescents: Replace immediate-release tablets when the 8-hour dosage corresponds to sustained-/extended-release tablet size; Ritalin SR may be administered once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22003063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22003063'])">Ref</a></span>). Usual maximum daily dose: 60 mg<b>/day</b>; however, some patients weighing &gt;50 kg may require and tolerate daily doses up to 100 mg/<b>day </b>with frequent monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Methylphenidate extended-release capsules (eg, generic Metadate CD): Children ≥6 years and Adolescents: Limited data available in ages &gt;15 years: Initial: 20 mg once daily; may increase by 10 to 20 mg/day increments at weekly intervals; usual maximum daily dose: 60 mg<b>/day</b>; however, some patients weighing &gt;50 kg may require and tolerate daily doses up to 100 mg/<b>day </b>with frequent monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">QuilliChew ER: Children ≥6 years and Adolescents: Initial: 20 mg once daily in the morning; may be adjusted in 10, 15, or 20 mg increments at weekly intervals (tablets are scored and may be broken in half to achieve dose); maximum daily dose: 60 mg/<b>day</b>. <b>Note:</b> If converting from another methylphenidate formulation, discontinue previous formulation and titrate QuilliChew ER using above schedule; do not substitute on a milligram-per-milligram basis.</p>
<p style="text-indent:-2em;margin-left:6em;">Quillivant XR: Children ≥6 years and Adolescents: Initial: 20 mg once daily in the morning; may increase by 10 to 20 mg/day increments at weekly intervals; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Relexxii:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Methylphenidate-naive patients:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥6 to ≤12 years: Initial: 18 mg once daily in the morning; may increase by 18 mg increments at weekly intervals up to 54 mg once daily; higher doses have not been studied. <b>Note:</b> Available in 27 mg, 45 mg, and 63 mg strengths for additional titration options.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents &lt;18 years: Initial: 18 mg once daily in the morning; may increase by 18 mg increments at weekly intervals up to 72 mg once daily or 2 mg/kg/day, whichever is lower; higher doses have not been studied. <b>Note:</b> Available in 27 mg, 45 mg, and 63 mg strengths for additional titration options.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents ≥18 years: Initial: 18 mg or 36 mg once daily in the morning; may increase by 18 mg increments at weekly intervals up to a maximum daily dose: 72 mg/<b>day</b>. <b>Note:</b> Available in 27 mg, 45 mg, and 63 mg strengths for additional titration options.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients currently receiving immediate-release methylphenidate:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥6 years and Adolescents:</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Current Methylphenidate IR Total Daily Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Relexxii Starting Dose</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">10 to 15 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">18 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 to 30 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;">36 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to 45 mg/day (eg, 15 mg 2 or 3 times daily)</p></td>
<td align="left">
<p style="text-indent:0em;">54 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">40 to 60 mg/day (eg, 20 mg 2 or 3 times daily)</p></td>
<td align="left">
<p style="text-indent:0em;">72 mg once daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Ritalin LA: Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Methylphenidate-naive patients:</i> Initial: 20 mg once daily; may increase by 10 mg/day increments at weekly intervals; usual maximum daily dose: 60 mg<b>/day</b>; however, some patients weighing &gt;50 kg may require and tolerate daily doses up to 100 mg/<b>day </b>with frequent monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453'])">Ref</a></span>). <b>Note:</b> If a lower initial dose is desired, patients may begin with Ritalin LA 10 mg once daily. Alternatively, patients may begin therapy with an immediate-release product, and switch to Ritalin LA once immediate-release dosage is titrated to 5 mg twice daily (see below).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients currently receiving immediate-release methylphenidate:</i> The same total daily dose of Ritalin LA should be used.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients currently receiving methylphenidate sustained release (SR):</i> The same total daily dose of Ritalin LA should be used.</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">
<i>Canadian labeling: </i></span></p>
<p style="text-indent:-2em;margin-left:8em;">Concerta: Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Sustained-release methylphenidate </i>[Canadian product]<i> to Concerta</i>: Oral:</p>
<p style="text-indent:-2em;margin-left:12em;">Switching from methylphenidate SR 20 mg daily: Concerta 18 mg once every morning.</p>
<p style="text-indent:-2em;margin-left:12em;">Switching from methylphenidate SR 40 mg daily: Concerta 36 mg once every morning.</p>
<p style="text-indent:-2em;margin-left:12em;">Switching from methylphenidate SR 60 mg daily: Concerta 54 mg once every morning.</p>
<p style="text-indent:-2em;margin-left:8em;">Biphentin [Canadian product]: Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Methylphenidate-naive patients:</i> Oral: Initial: 10 to 20 mg once daily; may be adjusted in 10 mg increments at weekly intervals; maximum daily dose: 60 mg/<b>day</b>. <b>Note:</b> In some children and adolescents, higher doses may be necessary; do not exceed 1 mg/kg/day or the adult maximum of 80 mg/<b>day</b>; monitor closely for adverse events, reduce dose or discontinue if adverse events occur.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients currently receiving immediate-release methylphenidate:</i> Use equivalent total daily dose administered once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Foquest [Canadian product]: Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Methylphenidate-naive patients:</i> Oral: Initial: 25 mg once daily; may be adjusted by 10 to 15 mg/day increments (based on available dosage forms) at ≥5-day intervals; maximum daily dose: 70 mg/<b>day</b> for patients &lt;18 years of age; 100 mg/<b>day</b> for patients ≥18 years of age.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients currently receiving immediate-release methylphenidate:</i> Calculate the patient's total daily methylphenidate dose and begin patient on the next lower strength.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: Transdermal patch (Daytrana): Children and Adolescents 6 to 17 years: Initial: 10 mg (12.5 cm<sup>2</sup>) patch once daily; apply to hip 2 hours before effect is needed and remove 9 hours after application (eg, 3 hours before bedtime); titrate dose based on response and tolerability; may increase to next transdermal patch dosage size no more frequently than every week. Patch may be removed before 9 hours if a shorter duration of action is required or if late day adverse effects appear or may be worn for up to 16 hours if extended duration of effects are needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17974748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17974748'])">Ref</a></span>). Plasma concentrations usually start to decline when the patch is removed but drug absorption may continue for several hours after patch removal. <b>Note:</b> The manufacturer's labeling recommends that patients converting from another formulation of methylphenidate to the transdermal patch should be initiated at 10 mg regardless of their previous dose and titrated as needed due to the differences in bioavailability of the transdermal formulation. However, some clinicians have supported higher starting patch doses for patients converting from oral methylphenidate doses of &gt;20 mg/day; for example, the 15 mg (18.75 cm<sup>2</sup>) patch has been investigated to have the same effect as 22.5 mg daily of the immediate-release preparation, 27 mg daily of the osmotic-release preparation (Concerta), or 20 mg daily of the encapsulated bead preparation (eg, generic Metadate CD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17974748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17974748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Approximate oral methylphenidate equivalents, with a 9-hour patch wear time, for the 20 mg and 30 mg patches are (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17974748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17974748'])">Ref</a></span>):</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center"></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Approximate oral equivalent daily dose</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Patch size (eg, Daytrana)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Immediate release (mg/day)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Osmotic release tablet (eg, Concerta) </b>
<b>(mg/day)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">15 mg (18.75 cm<sup>2</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">22.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">27 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 mg (25 cm<sup>2</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">36 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 mg (37.5 cm<sup>2</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">45 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">54 mg/day</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy:</b> Children ≥6 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablets and oral solution (Methylin, Ritalin): Initial: 5 mg twice daily given before breakfast and lunch; increase by 5 to 10 increments mg/day at weekly intervals; 2 to 3 times per day; maximum daily dose: 60 mg/<b>day</b> (in 2 to 3 divided doses).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-/sustained-release tablets (Metadate ER, Ritalin-SR): May be given in place of immediate-release products, once the immediate-release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained- or extended-release tablet size; maximum daily dose: 60 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129954"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); undergoes extensive metabolism to a renally eliminated metabolite with little or no pharmacologic activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51129955"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral, Transdermal: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56280504"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular events, including <b>acute myocardial infarctions</b> [MI], sudden cardiac death, stroke, <b>tachycardia</b>, and <b>increased blood pressure</b>, have been reported in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16549404','lexi-content-ref-22318795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16549404','lexi-content-ref-22318795'])">Ref</a></span>). Methylphenidate, similar to other CNS stimulants, has been associated with sudden death in children and adolescents with preexisting structural cardiac abnormalities. Available data in patients without congenital heart disease are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19528194','lexi-content-ref-23160939','lexi-content-ref-27245699','lexi-content-ref-22682429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19528194','lexi-content-ref-23160939','lexi-content-ref-27245699','lexi-content-ref-22682429'])">Ref</a></span>). A large retrospective cohort study showed an overall low incidence and risk of serious cardiovascular events in children and young adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22043968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22043968'])">Ref</a></span>); similarly, retrospective claims databases have not shown an increase in serious cardiovascular events (MI, sudden death, stroke) with stimulant use in young and middle-aged adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22161946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22161946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Methylphenidate increases the mean heart rate and systolic blood pressure by mediating the sympathetic, central and peripheral catecholaminergic systems (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12589522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12589522'])">Ref</a></span>). This increase in heart rate and blood pressure can ultimately lead to cardiovascular events such as arrhythmias and/or MI.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Increased risk for MI appeared after 1 week of treatment and persisted over 2 months. Arrhythmias and hypertension were reported to be more immediate adverse effects (day 1 to 3) and (day 4 to 7) after initiation of treatment respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27245699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27245699'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with prior structural heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22318795','lexi-content-ref-27245699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22318795','lexi-content-ref-27245699'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of QTc prolonging medications may increase the risk of arrhythmias</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Growth suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Some studies have reported <b>growth retardation</b> in pediatric patients. Decreased height and weight changes have been described in children &lt;12 years receiving long-term treatment (ie, ≥3 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26544899','lexi-content-ref-26608309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26544899','lexi-content-ref-26608309'])">Ref</a></span>). Similarly, statistically significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed in pediatric patients (age range: 8 to 17 years) actively treated with stimulants (including but not limited to methylphenidate) when compared to matched unmedicated controls; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched controls (38.3% to 21.6%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26398435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26398435'])">Ref</a></span>). An association has been observed between cumulative methylphenidate exposure in childhood and decreased height velocity, decreased adult height, and increased weight in adulthood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421233'])">Ref</a></span>). In contrast, a longitudinal cohort-controlled trial reported no difference in peak height velocity and final adult height in subjects with ADHD and/or treated with stimulants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25180281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25180281'])">Ref</a></span>). In adults, methylphenidate has been shown to cause anorexia with weight loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14981214']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14981214'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Possibly due to effects on central nervous system growth factors and hepatic growth factors and direct cartilage effects. Weight loss may result from appetite suppression, reduced food intake, increased activity, and metabolic shifts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9685453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9685453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Growth suppression in children: Delayed; appears to occur after months of active treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3058088','lexi-content-ref-31473291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3058088','lexi-content-ref-31473291'])">Ref</a></span>). Appetite suppression in adults: Immediate; occurs within hours of initiation of therapy and after only one dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21733284','lexi-content-ref-14981214']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21733284','lexi-content-ref-14981214'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of treatment/cumulative methylphenidate exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421233','lexi-content-ref-3058088','lexi-content-ref-31473291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421233','lexi-content-ref-3058088','lexi-content-ref-31473291'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Priapism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Priapism </b>associated with neurostimulants like methylphenidate has been reported in the literature and published in an FDA Drug Safety Communication. The presentation of priapism has ranged in severity, occurred with dose changes and withdrawal of the medication, and has been reported with different dosage forms and products (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>). The overall incidence of methylphenidate-induced priapism is unknown. In severe cases, priapism (ischemic) can be a urological emergency and may require surgical interventions to prevent permanent erectile dysfunction, fibrosis, and impotence.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Prolonged erections occur when the balance of the smooth muscle cell (SMC) control system is altered towards SMC relaxation; ischemic priapism results when the inflow and outflow of blood is halted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18087648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18087648'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; may be related to the half-life of the medication/formulation. Case reports have reported onset of priapism within a few hours of ingesting immediate-release methylphenidate or the day after taking sustained release methylphenidate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21043394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21043394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hematological dyscrasias (eg, sickle cell disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Malignancies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Perineal trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of illicit drugs known to cause priapism (eg, cocaine, ecstasy, marijuana) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of prescription medications associated with priapism (eg, psychotropic medications [typical and atypical antipsychotics, antidepressants, and anxiolytics], alpha-adrenergic agents, anticoagulants) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric/behavioral effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset <b>psychosis</b> or <b>mania</b> and exacerbation of psychotic or manic symptoms (eg, delusional thinking<b>, auditory hallucination and visual hallucination</b>, mania) may occur with neurostimulant use in all ages; methylphenidate has also been associated with <b>aggressive behavior</b> or hostility in children; however, a causal relationship has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19171629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19171629'])">Ref</a></span>). A recent cohort study in adolescents and young adults failed to show any evidence that the initiation of methylphenidate increased the risk of psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31221557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31221557'])">Ref</a></span>). Patients with ADHD are at increased risk for suicidal ideation and suicide attempt; however, neither increased risk nor a causal relationship with methylphenidate and attempted suicide has been observed in large cohort trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29501070','lexi-content-ref-28746699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29501070','lexi-content-ref-28746699'])">Ref</a></span>). The risk of psychosis may be lower with methylphenidate compared to amphetamine products (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Psychosis: Central stimulants amplify neuronal signaling by increasing in dopamine concentration in the prefrontal cortex of the brain. Increased dopamine levels have been associated with the development of psychotic and manic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1681750','lexi-content-ref-31221557','lexi-content-ref-22474070','lexi-content-ref-19171629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1681750','lexi-content-ref-31221557','lexi-content-ref-22474070','lexi-content-ref-19171629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Days to weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31221557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31221557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting history of psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26485338','lexi-content-ref-31221557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26485338','lexi-content-ref-31221557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of mood and psychotic disorders (eg, major depression, bipolar disorder, schizophrenia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26719291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26719291'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Young age (children, adolescents, and young adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26485338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26485338'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F195263"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (2% to 26%), nausea (2% to 13%), xerostomia (oral: 3% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2% to 22%, including migraine; tension headache: oral: 1%), insomnia (including initial insomnia; oral: 2% to 33%; transdermal: 6% to 13%), irritability (2% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (≥2%), increased diastolic blood pressure (oral: 7%), palpitations (3%), tachycardia (oral: 5%; transdermal: ≤1%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 1</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption>
<b>Methylphenidate: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Methylphenidate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methylphenidate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">85</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">145</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">72</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Excoriation of skin (oral: 4%), hyperhidrosis (oral: 5%), skin rash (oral: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (oral: 2%), weight loss (2% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Weight Loss table link" class="lexi-table-link" data-table-id="lexi-content-weight-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-loss')">table 2</a>)</span><span class="table-link" style="display:none;">Weight Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Loss" frame="border" id="lexi-content-weight-loss" rules="all">
<caption>
<b>Methylphenidate: Adverse Reaction: Weight Loss</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Methylphenidate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methylphenidate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">85</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 60 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release chewable tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">42</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">44</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 to 85 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">145</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">72</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 to 100 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">297</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">78</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5% to 7%), anorexia (2% to 9%), bruxism (oral: 2%), constipation (oral: 1%), diarrhea (oral: 4%), dyspepsia (oral: 2%), motion sickness (oral: 2%), upper abdominal pain (oral: 4% to 9%), vomiting (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (oral: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (oral: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (oral: 2%)<span class="lexi-table-link-container"> (<a aria-label="Aggressive Behavior table link" class="lexi-table-link" data-table-id="lexi-content-aggressive-behavior" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-aggressive-behavior')">table 3</a>)</span><span class="table-link" style="display:none;">Aggressive Behavior</span>, agitation (oral: 2%), anxiety (oral: 8%), confusion (oral: 1%), depressed mood (oral: 4%), depression (2%), dizziness (2% to 7%), emotional lability (1% to 9%), fatigue (3%), hypertonia (oral: 2%), jitteriness (oral: 4%), lack of emotion (oral: 2%), nervousness (3%) paresthesia (1%), psychomotor agitation (oral: 5%), restlessness (oral: 3%), sedated state (oral: 1%), tension (oral: 1%), tic disorder (1% to 9%), tremor (oral: 3%), vertigo (oral: 2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Aggressive Behavior" frame="border" id="lexi-content-aggressive-behavior" rules="all">
<caption>
<b>Methylphenidate: Adverse Reaction: Aggressive Behavior</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Methylphenidate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Methylphenidate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 60 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release chewable tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">42</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">44</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Attention deficit hyperactivity disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">415</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (oral: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (2%), eye pain (oral: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (oral: 2%), nasopharyngitis (oral: 3%), oropharyngeal pain (oral: 1% to 2%), streptococcal pharyngitis (oral: 3%), upper respiratory tract infection (oral: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (oral: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Dermatologic: Contact hypersensitivity (transdermal)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart murmur, hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Macular eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash, increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, viral gastroenteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium, drug abuse, drug dependence, Gilles de la Tourette syndrome, hypervigilance, lethargy, outbursts of anger, panic attack, toxic psychosis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, dyspnea, sinusitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Drug tolerance</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Thompson 2010), angina pectoris, bradycardia, cardiac arrhythmia (Shin 2016), cardiomyopathy (Nymark 2008), chest discomfort, chest pain, extrasystoles, necrotizing angiitis, peripheral vascular insufficiency, Raynaud disease (Goldman 2008), supraventricular tachycardia, syncope (Ferahkaya 2022), ventricular arrhythmia (Schelleman 2012), ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Ardic 2017), bullous skin disease, erythema multiforme, erythema of skin, exfoliative dermatitis, fixed drug eruption (Cohen 1992), leukoderma (transdermal: chemical) (Cheng 2017; FDA Safety Alert 2015), pruritus (Storebø 2018), urticaria (Storebø 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Growth retardation (Poulton 2016; Storebø 2015), gynecomastia (Ensat 2012), heavy menstrual bleeding (Özdağ 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism (Eiland 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia (Grossman 1985), pancytopenia, thrombocytopenia (Ercan 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (Lewis 2007), hepatic failure (acute), increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Goyal 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior, asthenia (Storebø 2018), auditory hallucination (Mosholder 2009), cerebral arteritis (Storebø 2018), disorientation, drowsiness (Storebø 2018), extrapyramidal reaction, hyperactive behavior, hyperpyrexia, hypomania (Storebø 2018), mania (Mosholder 2009), mood changes (Storebø 2018), obsessive compulsive disorder, psychosis (Storebø 2018), seizure (Andrade 2020), sleep disorder (Storebø 2018), talkativeness (Storebø 2018), visual hallucination (Mosholder 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, dyskinesia (including choreiform movements) (Storebø 2018), dystonia (Uzun 2018), muscle twitching, myalgia, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Swelling of the ear</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (Chandradasa 2019)</p></div>
<div class="block coi drugH1Div" id="F195278"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i> Hypersensitivity (eg, angioedema, anaphylaxis) to methylphenidate or any component of the formulation (including film backing and adhesives for transdermal product); use during or within 14 days following MAOI therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications:</p>
<p style="text-indent:-2em;margin-left:4em;">Methylphenidate ER capsules (generic Metadate CD): Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to methylphenidate or any component of the formulation; marked anxiety, tension, and agitation; glaucoma; use during or within 14 days following monoamine oxidase inhibitor therapy; family history or diagnosis of Tourette syndrome or tics (excluding Concerta); thyrotoxicosis; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; history of drug abuse (excluding Concerta).</p>
<p style="text-indent:-2em;margin-left:4em;">Additional contraindications:</p>
<p style="text-indent:-2em;margin-left:6em;">Foquest: Known hypersensitivity or idiosyncrasy to sympathomimetic amines; history of drug abuse.</p>
<p style="text-indent:-2em;margin-left:6em;">Ritalin and Ritalin SR: Pheochromocytoma.</p></div>
<div class="block war drugH1Div" id="F195260"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Acute angle closure glaucoma and increased intraocular pressure (IOP) have been reported with treatment. Evaluation by an ophthalmologist prior to treatment is recommended in patients at risk for acute angle closure glaucoma (eg, patients with significant hyperopia); use in patients with open angle glaucoma or increased IOP only if benefits outweigh risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Peripheral vasculopathy effects have been observed at different times, at therapeutic doses, and in all age groups. Digital ulceration and/or soft tissue breakdown have been observed; further evaluation (eg, rheumatology) may be necessary in patients developing signs and symptoms of peripheral vasculopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual disturbance: Difficulty in accommodation and blurred vision have been reported with the use of stimulants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bipolar disorder: May precipitate a mixed or manic episode in patients with bipolar illness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disorders: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity. Discontinue in the presence of seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation; use is contraindicated with some products.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adhansia XR: 45 mg capsules contain FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Biphentin, Foquest [Canadian products]: Controlled-release capsules are not interchangeable with other controlled-release formulations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Concerta, Relexxii: Should not be used with preexisting severe gastrointestinal narrowing conditions, such as esophageal motility disorders, small bowel disease, “short” gut syndrome, cystic fibrosis, history of peritonitis, chronic intestinal pseudo-obstruction, or Meckel diverticulum.</p>
<p style="text-indent:-2em;margin-left:4em;">• Daytrana: Transdermal system may cause dermal reactions: Chemical leukoderma and contact sensitization; in a one-year tolerability study, the majority of subjects who withdrew (7%) did so due to dermal reactions (Findling 2009). Chemical leukoderma is a persistent loss of skin pigmentation at and around the application site, as well as at distant sites from the application site, that may resemble vitiligo, especially if loss of skin pigmentation occurs at areas distant from application site; patients with a personal and/or family history of vitiligo may be at more risk; patients should monitor for signs of skin depigmentation and immediately inform their health care provider if observed; discontinue use if patient experiences chemical leukoderma; loss of skin pigmentation may continue after discontinuation. Contact sensitization is characterized by erythema plus an intense local reaction (eg, edema, papules, vesicles) that does not improve within 48 hours or spreads beyond the patch site; sensitization may subsequently manifest systemically with other routes of methylphenidate administration; if using oral methylphenidate, initiate under medical supervision and monitor closely, as some sensitized patients may not be able to take methylphenidate in any form. Avoid exposure of application site to any direct external heat sources (eg, hair dryers, heating pads, electric blankets) while wearing patch; heat may increase the rate and extent of absorption more than 2-fold and result in overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose/sucrose: Some dosage forms may contain lactose or sucrose; use with caution in patients intolerant to either component (some manufacturer labels recommend avoiding use in such patients).</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylketonuria: Some dosage forms contain phenylalanine, which can be harmful to patients with phenylketonuria. Before prescribing, consider the combined daily amount of phenylalanine from all sources.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878545"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution in preschool-age children; some clinical trials have reported higher rates of adverse events in children 3 to 5 years of age, compared with older children, and some trials have noted a greater discontinuation of therapy compared to school-age children, though adverse event reports may have been a proxy for inefficacy, rebound, or other underlying causes (Greenhill 2006; Wigal 2006). Although efficacious (Childress 2020; Childress 2022), the 12-month open-label phase of a previous multicenter placebo-controlled trial using the extended-release tablet (Aptensio XR) reported half (n=20/39) of patients 4 to &lt;6 years of age experienced enough lost weight to decrease ≥10 percentiles on CDC growth charts; systemic exposure (AUC, C<sub>max</sub>) was also reported to be 2 to 3 times higher than older children and adolescents (same dose) (manufacturer's labeling).</p></div>
<div class="block prod-avail drugH1Div" id="F58646361"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Adhansia XR has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block dosfc drugH1Div" id="F50474161"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Aptensio XR capsules contain multi layered beads. The immediate release layer delivers approximately 40% of the methylphenidate dose, and the controlled release layer delivers approximately 60% of the methylphenidate dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Concerta is an osmotic controlled release formulation (OROS) of methylphenidate. The tablet has an immediate-release overcoat providing an initial dose of methylphenidate within 1 hour, and the remaining is released at a controlled rate over 5-9 hours. The overcoat covers a trilayer core. The trilayer core is composed of two layers containing the drug and excipients, and one layer of osmotic components. As water from the gastrointestinal tract enters the core, the osmotic components expand and methylphenidate is released.</p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate ER capsules (generic Metadate CD) contain a mixture of immediate release and extended release beads, designed to release 30% of the dose immediately and 70% over an extended period.</p>
<p style="text-indent:-2em;margin-left:2em;">Ritalin LA uses Spheroidal Oral Drug Absorption System (SODAS) design to deliver a bimodal release of medication, intended to mimic twice-daily administration of immediate-release methylphenidate. Fifty percent of the drug is delivered in immediate-release beads, and the remaining half is delivered in delayed-release beads approximately 4 hours after administration.</p></div>
<div class="block foc drugH1Div" id="F195272"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adhansia XR: 25 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adhansia XR: 35 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adhansia XR: 45 mg [DSC] [contains fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adhansia XR: 55 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adhansia XR: 70 mg [DSC], 85 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptensio XR: 10 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptensio XR: 15 mg [contains fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptensio XR: 20 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptensio XR: 30 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptensio XR: 40 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptensio XR: 50 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptensio XR: 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jornay PM: 20 mg, 40 mg, 60 mg, 80 mg, 100 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ritalin LA: 10 mg, 20 mg, 30 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Daytrana: 10 mg/9 hr (1 ea, 30 ea); 15 mg/9 hr (1 ea, 30 ea); 20 mg/9 hr (1 ea, 30 ea); 30 mg/9 hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/9 hr (1 ea, 30 ea); 15 mg/9 hr (1 ea, 30 ea); 20 mg/9 hr (1 ea, 30 ea); 30 mg/9 hr (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methylin: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL) [contains polyethylene glycol (macrogol); grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (5 mL, 500 mL); 10 mg/5 mL (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Quillivant XR: 25 mg/5 mL (60 mL, 120 mL, 150 mL, 180 mL) [contains corn starch, sodium benzoate; banana flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ritalin: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ritalin: 10 mg, 20 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">QuilliChew ER: 20 mg, 30 mg [scored; contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">QuilliChew ER: 40 mg [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Concerta: 18 mg, 27 mg, 36 mg, 54 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relexxii: 18 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relexxii: 27 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relexxii: 36 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relexxii: 45 mg [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relexxii: 54 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relexxii: 63 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Relexxii: 72 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 18 mg, 20 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg, 72 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 18 mg, 27 mg, 36 mg, 54 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cotempla XR-ODT: 8.6 mg, 17.3 mg, 25.9 mg</p></div>
<div class="block geq drugH1Div" id="F195256"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F5989423"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Aptensio XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $10.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $10.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $10.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $10.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $10.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $10.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $10.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Jornay PM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $18.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $18.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $18.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $18.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $18.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Methylphenidate HCl ER (LA) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $10.27 - $12.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $5.67 - $12.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $5.80 - $13.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $5.96 - $13.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $12.37 - $14.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Methylphenidate HCl ER (XR) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $7.17 - $9.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $7.17 - $9.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $7.17 - $9.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $7.17 - $9.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.17 - $9.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $7.17 - $9.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $7.17 - $9.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Ritalin LA Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $13.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $13.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $14.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $14.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Extended Release</b> (Methylphenidate HCl ER (CD) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $5.60 - $8.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $5.60 - $8.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $5.60 - $8.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.12 - $11.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $9.44 - $14.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $9.44 - $14.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Methylphenidate HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $1.92 - $3.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.23 - $4.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.54 - $6.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Daytrana Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/9 hrs (per each): $7.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/9 hrs (per each): $7.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/9 hrs (per each): $7.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/9 hrs (per each): $7.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Methylphenidate Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/9 hrs (per each): $16.76 - $17.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/9 hrs (per each): $16.76 - $17.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/9 hrs (per each): $16.76 - $17.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/9 hrs (per each): $16.76 - $17.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methylin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $0.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methylphenidate HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.25 - $0.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $0.38 - $1.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (Quillivant XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $3.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Chewable Extended Release</b> (QuilliChew ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $14.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $14.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $14.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Extended Release Dispersible</b> (Cotempla XR-ODT Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8.6 mg (per each): $19.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17.3 mg (per each): $19.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25.9 mg (per each): $19.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Methylphenidate HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg (per each): $6.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27 mg (per each): $6.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">36 mg (per each): $6.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">54 mg (per each): $7.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Concerta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg (per each): $15.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27 mg (per each): $15.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">36 mg (per each): $16.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">54 mg (per each): $17.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Methylphenidate HCl ER (OSM) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg (per each): $0.89 - $13.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27 mg (per each): $0.89 - $13.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">36 mg (per each): $1.06 - $13.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $22.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">54 mg (per each): $1.06 - $15.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">63 mg (per each): $24.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">72 mg (per each): $24.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Methylphenidate HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $7.50 - $8.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $7.75 - $8.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Relexxii Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg (per each): $14.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27 mg (per each): $14.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">36 mg (per each): $15.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $25.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">54 mg (per each): $16.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">63 mg (per each): $26.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methylphenidate HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.61 - $0.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.36 - $1.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.34 - $1.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ritalin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867531"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 15 mg [contains d&amp;c red #28, fd&amp;c red #40 (allura red ac dye), quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 80 mg [contains fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 10 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 20 mg [contains d&amp;c red 33, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 30 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 40 mg [contains d&amp;c red #28, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 50 mg [contains quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biphentin: 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Foquest: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Foquest: 25 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Foquest: 35 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Foquest: 45 mg [contains fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Foquest: 55 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Foquest: 70 mg, 85 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ritalin: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Concerta: 18 mg, 27 mg, 36 mg, 54 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ritalin SR: 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 18 mg, 20 mg, 27 mg, 36 mg, 54 mg</p></div>
<div class="block csi drugH1Div" id="F195330"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block adm drugH1Div" id="F195275"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Short-acting immediate release:</b> Chewable tablets, Methylin (oral solution), and Ritalin (tablets):</i> Administer each dose 30 to 45 minutes before a meal. Ensure last daily dose is administered before 6:00 PM if difficulty sleeping occurs. Administer chewable tablet with ≥8 ounces of water or other fluid.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Intermediate-acting extended release</b></i>
<i>
<b>: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Metadate ER:</i> Administer 30 to 45 minutes before a meal. Swallow whole with water or other fluid; do not crush or chew tablet.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Ritalin SR [Canadian product]:</i> Swallow whole; do not crush or chew tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Long-acting extended release:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adhansia XR: </i>Administer in the morning with or without food. Swallow whole with full glass of water; do not crush or chew capsules. Alternatively, capsules may be opened and the contents sprinkled onto a tablespoon of applesauce or yogurt. Swallow mixture immediately or within 10 minutes without chewing; discard if not administered within 10 minutes of mixing. Do not crush, chew, or divide capsule contents.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Aptensio XR, Jornay PM, methylphenidate ER capsule (generic Metadate CD), Ritalin LA:</i> Administer Aptensio XR, methylphenidate ER capsule (generic Metadate CD), and Ritalin LA in the morning and Jornay PM in the evening between 6:30 PM to 9:30 PM. Administer with or without food; capsules may be opened, and the contents sprinkled onto a small amount (equal to 1 tablespoon) of cold applesauce. Swallow applesauce mixture immediately without chewing. Do not crush, chew, or divide capsule contents.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Biphentin, Foquest [Canadian products]:</i> Administer in the morning. Swallow whole with full glass of water; do not crush or chew capsules. Alternatively, capsules may be opened, and the contents sprinkled onto applesauce, ice cream, or yogurt, but the beads must not be crushed or chewed.</p>
<p style="text-indent:-2em;margin-left:8em;">Biphentin should be administered immediately after or within 30 minutes of sprinkling capsule contents on food; after administration patients should rinse their mouths with water and swallow. Discard if not administered within 30 minutes of mixing.</p>
<p style="text-indent:-2em;margin-left:8em;">Foquest should be administered immediately after or within 10 minutes of sprinkling capsule contents on food; after administration patients should rinse their mouths with water and swallow. Discard if not administered within 10 minutes of mixing.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concerta, Relexxii:</i> Administer in the morning. May be taken with or without food but must be taken with water or other fluid. Do not crush, chew, or divide tablet.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>QuilliChew ER:</i> Administer in the morning with or without food. Tablets are scored and may be halved.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Quillivant XR:</i> Administer in the morning with or without food. Shake bottle ≥10 seconds prior to administration. Use the oral dosing dispenser provided; wash after each use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Bariatric surgery:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tablet, extended release:</i> Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablets should be swallowed whole. Do not cut, chew, or crush. IR tablet, chewable tablet, oral solution, and oral suspension formulations are available. ER chewable tablet, ER orally dissolvable tablet, and transdermal formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close clinical monitoring is advised in the immediate postoperative phase for the theoretical circumstance of altered absorption after bariatric surgery.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Topical: <i>Long-acting transdermal:</i></b>
<i>Daytrana:</i> Apply to clean, dry, non-oily, intact skin to the hip area, avoiding the waistline; do not premedicate the patch site with hydrocortisone or other solutions, creams, ointments, or emollients. Apply at the same time each day to alternating hips. Press firmly for 30 seconds to ensure proper adherence. Avoid exposure of application site to external heat source, which may increase the amount of drug absorbed. If difficulty is experienced when separating the patch from the liner or if any medication (sticky substance) remains on the liner after separation, discard that patch and apply a new patch. Do not use a patch that has been damaged or torn; do not cut patch. If patch should dislodge, may replace with new patch (to different site) but total wear time should not exceed 9 hours; do not reapply with dressings, tape, or common adhesives. Patch may be removed early if a shorter duration of effect is desired or if late day side effects occur. Wash hands with soap and water after handling. Avoid touching the sticky side of the patch. If patch removal is difficult, an oil-based product (eg, petroleum jelly, olive oil) may be applied to the patch edges to aid removal; never apply acetone-based products (eg, nail polish remover) to patch. Dispose of used patch by folding adhesive side onto itself, and discard in toilet or appropriate lidded container; do not flush the pouch or liner down the toilet.</p></div>
<div class="block admp drugH1Div" id="F52613307"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: To avoid insomnia, last daily dose of all products except Jornay PM should be administered several hours before retiring.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate-release formulations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Tablet (Ritalin), oral solution (Methylin): Administer ~30 to 45 minutes before meals. Ensure last daily dose is administered before 6 PM if difficulty sleeping occurs.</p>
<p style="text-indent:-2em;margin-left:6em;">Chewable tablet (Methylin): Administer ~30 to 45 minutes before meals with at least 8 ounces of water or other fluid; choking may occur if not enough fluids are taken. Ensure last daily dose is administered before 6 PM if difficulty sleeping occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-/sustained-release formulations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Tablets:</p>
<p style="text-indent:-2em;margin-left:8em;">Concerta: May be administered without regard to food, but must be taken with liquids; administer dose once daily in the morning; do not crush, chew, or divide tablets.</p>
<p style="text-indent:-2em;margin-left:8em;">Metadate ER: May be taken with or without food. Swallow whole; do not crush, chew, or break tablets.</p>
<p style="text-indent:-2em;margin-left:8em;">Relexxii: May be administered without regard to food; swallow whole with liquid; do not crush, chew, or divide tablets.</p>
<p style="text-indent:-2em;margin-left:8em;">Ritalin SR: Administer 30 to 45 minutes before a meal. Swallow whole; do not crush, chew, or break tablets.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsules:</p>
<p style="text-indent:-2em;margin-left:8em;">Adhansia XR: Administer in the morning with or without food; swallow capsule whole; do not crush, chew, or divide capsule or its contents. Capsules may be opened and entire contents sprinkled onto a tablespoon of applesauce or yogurt; use within 10 minutes (immediately use is preferable); mixture must be consumed without chewing; do not store for future use. Missed doses should not be administered later in the day, and do not administer additional doses to make up for missed dose; resume normal dosing regimen the next morning.</p>
<p style="text-indent:-2em;margin-left:8em;">Aptensio XR: Administer in the morning with or without food; swallow capsule whole; do not crush, chew, or divide capsule or its contents; capsules may be opened and the contents sprinkled onto applesauce; mixture must be consumed immediately without chewing; do not store for future use.</p>
<p style="text-indent:-2em;margin-left:8em;">Biphentin [Canadian product]: Administer in the morning; do not crush or chew capsule or its contents; capsules may be opened and the contents sprinkled onto applesauce, ice cream, or yogurt; mixture must be consumed immediately without chewing; do not store for future use.</p>
<p style="text-indent:-2em;margin-left:8em;">Foquest [Canadian product]: Administer in the morning with a full glass of water; do not crush or chew capsule or its contents; capsules may be opened and the contents sprinkled onto a tablespoon of applesauce, ice cream, or yogurt; mixture must be consumed within 10 minutes without chewing.</p>
<p style="text-indent:-2em;margin-left:8em;">Jornay PM: Administer dose once daily in the evening between 6:30 and 9:30 PM; administer consistently either with or without food; swallow capsule whole; do not crush, chew, or divide capsule or its contents; capsules may be opened and the contents sprinkled onto applesauce; mixture must be consumed immediately without chewing; do not store for future use. Missed doses should be taken as soon as remembered if the same evening; if missed dose remembered the following morning, it should be skipped.</p>
<p style="text-indent:-2em;margin-left:8em;">Methylphenidate extended-release capsules (eg, generic Metadate CD): Administer dose once daily in the morning, before breakfast, with liquids; capsule may be swallowed whole; do not crush, chew, or divide capsule or its contents; capsules may be opened and contents sprinkled on a small amount (one tablespoonful) of applesauce; immediately consume drug/applesauce mixture; do not store for future use; swallow applesauce without chewing; drink fluids after consuming drug/applesauce mixture to ensure complete swallowing of beads.</p>
<p style="text-indent:-2em;margin-left:8em;">Ritalin LA: Administer dose once daily in the morning; may be administered with or without food (but some food consumed at breakfast may delay absorption); capsule may be swallowed whole; do not crush, chew, or divide capsule or its contents; may be opened and contents sprinkled on a small amount (one spoonful) of applesauce. <b>Note:</b> Applesauce should not be warm; immediately consume drug/applesauce mixture; do not store for future use.</p>
<p style="text-indent:-2em;margin-left:6em;">Orally disintegrating tablet (Cotempla XR-ODT): Administer in the morning consistently with or without food. Remove the tablet from blister pack with dry hands by peeling back (do not push tablet through foil), and administer immediately. Allow the tablet to dissolve on the tongue without chewing or crushing; no liquid is needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Powder for oral suspension (Quillivant XR): Administer in the morning with or without food. Shake bottle ≥10 seconds prior to administration. Use the oral dosing dispenser provided; wash after each use.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: <i>Transdermal</i> (Daytrana): Apply patch immediately after opening pouch and removing protective liner; do not use patch if pouch seal is broken; do not cut patch; do not use patches that are cut or damaged. If difficulty is experienced when separating the patch from the liner or if any medication (sticky substance) remains on the liner after separation, discard that patch and apply a new patch. Apply to clean, dry, healthy skin on the hip; do not apply to oily, damaged, inflamed, or irritated skin; do not apply to the waistline; do not premedicate the patch site with hydrocortisone or other solutions, creams, ointments, or emollients. Apply at the same time each day, 2 hours before effect is needed. Alternate site of application daily (ie, use alternate hip). Press patch firmly for 30 seconds to ensure proper adherence, especially around the edges. Remove patch typically 9 hours after application. Patch may be removed earlier if a shorter duration of action is required or if late day adverse effects occur or may be worn for up to 16 hours if extended duration of effects are needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17974748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17974748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Avoid exposure of application site to external heat source (eg, hair dryers, electric blankets, heating pads, heated water beds), which may significantly increase the rate and amount of drug absorbed. Exposure of patch to water during swimming, bathing, or showering may affect patch adherence. Do not reapply patch with dressings, tape, or other adhesives. If patch should become dislodged, may replace with new patch (to different site) but total wear time for the day should not exceed 9 hours, even if more than one patch is used.</p>
<p style="text-indent:-2em;margin-left:4em;">During removal, peel off patch slowly. If needed, patch removal may be helped by applying an oil-based product (ie, mineral oil, olive oil, or petroleum jelly) to the patch edges, gently working it underneath the patch edges. If a patch is not able to be removed, contact a physician or pharmacist. Nonmedical adhesive removers and acetone-based products, such as nail polish remover, should not be used to remove patches or adhesive. If adhesive residue remains on the skin after patch removal, use an oil-based product and gently rub area to remove adhesive. Avoid touching the sticky side of the patch. Wash hands with soap and water after handling.</p>
<p style="text-indent:-2em;margin-left:4em;">Dispose of used patch by folding adhesive side onto itself, and flush down the toilet or discard in appropriate lidded container; discard unused patches that are no longer needed in the same manner; protective pouch and liner should be discarded in an appropriate lidded container. <b>Note:</b> Used patches contain residual drug; keep all transdermal patches out of the reach of children.</p></div>
<div class="block meg drugH1Div" id="F7874704"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Adhansia XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F212038s002lbl.pdf%23page%3D25&amp;token=PQ4UQw20gZBnu%2FdLwdCR1k6xngnHIfAp64IeTwox7JA58yoeFpdFzeR1QL%2BOeObvr9UhT0X3JI04KCDpuXxlRwqLgng%2BfYye6tA6tbu%2BFKaH%2B92JRy68B9k6Ew%2B1b1Ep&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212038s002lbl.pdf#page=25</a></p>
<p style="text-indent:-2em;margin-left:4em;">Aptensio XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F205831s008lbl.pdf%23page%3D19&amp;token=0xArWZkun6glelWIj5kLrOikQiSFlYadt1GcnVB%2Fm82WW%2BPRda75o6DwJkg7kbUfweC7nIRDSdGG%2FQZrKVWbYfEHYQP2kgp67UtFiLuAKTiPVzUnCkEDNl7wIl7HpzI1&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205831s008lbl.pdf#page=19</a></p>
<p style="text-indent:-2em;margin-left:4em;">Concerta: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021121s049lbl.pdf%23page%3D30&amp;token=tI6p%2F2HMNCQ1FuIVvRvvN1c8y4Xw41L1i0J6jA%2FHAO6ZR9EwCVtx%2BakYkTjZje6tN5Kcp1pnCrqVontT7ENBmZHWYcH1ygkcuxE80rfIjJhiPcREusMmgM0kKl0tWs2Z&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021121s049lbl.pdf#page=30</a></p>
<p style="text-indent:-2em;margin-left:4em;">Cotempla XR-ODT: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F205489s012lbl.pdf%23page%3D24&amp;token=VYcJPT4fRm4Vbhh5RemppObXXFICcAMmHwxvv4hnDrbZLC58YewgqUA6K5xY%2F8bZPEhMvK2283JCSaOpQ8PnZ3wsv5KfMZ%2BdjECnjOuaUyd%2Ff5gITiw4FmcRGKyWf0L9&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205489s012lbl.pdf#page=24</a></p>
<p style="text-indent:-2em;margin-left:4em;">Daytrana: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021514s036lbl.pdf%23page%3D25&amp;token=S1pfATlhGMWttYGsVL7i6jMofY4b7jk%2BzpRKNF6JqRqEAlRFLhZAKLFIs%2BYAbZsz8HHP9FC0790OTvDbr5C%2FTGPi2ujEwEn0SB5JnuFTYDNXtlQM66%2BCEculu4gbKVKu&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021514s032lbl.pdf#page=25</a></p>
<p style="text-indent:-2em;margin-left:4em;">Jornay PM: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F209311s010lbl.pdf%23page%3D20&amp;token=xX%2BhOlX372d9Jz%2BybMxQozQiuivOMmHetQXDrxxePGo82Lr%2FzcpkYgImavHxtRRCuhdUerT7k8Uk6fglPEUCB1eo2cUqcHkkvpKLwLi97snPYGVgCINsEuKYVfQlozC0&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209311s010lbl.pdf#page=20</a></p>
<p style="text-indent:-2em;margin-left:4em;">Metadate CD: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021259s034lbl.pdf%23page%3D16&amp;token=2qffI8ZgjU4DxO8lxasHwcu2%2Figp3JjgxyR9Bu%2F4QvdDzknIMT4JUoFDfG%2FDm0aGj%2FOqE9tziC2x%2BVmVEtpxykabe4PgoAa3Xkne0G7q%2F6ewkY3t6Bl%2F1tIZv0BRJM%2FU&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021259s034lbl.pdf#page=16</a></p>
<p style="text-indent:-2em;margin-left:4em;">Methylin chewable tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021475s012lbl.pdf%23page%3D13&amp;token=w%2Bqfyl11AzX2CakqwTlx0%2FJ1QiqdcUOVavfoFx5eOL6yAcUgmiOC4%2FS1hOggzlVN5xS%2B7Q7sOb%2FaCUFFso1LhbHLmycPNV4Rs2zhOV1paS6UAqLc4F%2BGnK7ShrrneQhD&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021475s012lbl.pdf#page=13</a></p>
<p style="text-indent:-2em;margin-left:4em;">Methylin oral solution: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021419s023lbl.pdf%23page%3D17&amp;token=46eRf0Huz97m8CzYeXz0GTYd5zJhIUS9R1N7RvGDm4aqYUFQxi3TU5eTx1VAJ9%2F1gXWQODkv4j7%2B%2BDMtxwLHSvWc8RZiHU7hqfzDH7iU6I60ueqeOcubBVyJ2QvF1fXU&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021419s023lbl.pdf#page=17</a></p>
<p style="text-indent:-2em;margin-left:4em;">QuilliChew ER: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F207960s012lbl.pdf%23page%3D21&amp;token=EIK5IQV6mKBAheSVS16Gbza0HaxspiTzHUmEtXQAF4n9WI27XAHIaExDWfbxZt9Io5%2F4XaV%2FqbR2UWgqboUvLtAX0oxdTaxUxFaOOqn5tWWHC7Rb2FimMC6v9aHXbCxy&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207960s012lbl.pdf#page=21</a></p>
<p style="text-indent:-2em;margin-left:4em;">Quillivant XR extended release oral suspension: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F202100s018lbl.pdf%23page%3D21&amp;token=Q3GuT07QfEWUyNxwc24V5lUAsLHxvX9ZNAM8dEnHlcQJmJN%2FUXHLElCixpQ7y2ynTb%2B%2BGiNnPOEDVZK1oSj6jtybaY5dteCb3rcnwxEjbzPajMkhnyZMpLpo74PcZMC9&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202100s018lbl.pdf#page=21</a></p>
<p style="text-indent:-2em;margin-left:4em;">Relexxii: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F216117s001lbl.pdf%23page%3D25&amp;token=JiaFw53QYldqlhg4mkDEXSAnaSm8kaA06PpiNE83OZ6Ns%2BdhZRp57qTfyhXG9%2FslxvERU5uMd%2BILVnRcN8e1XgXprh60iDPxDXjzvcUZ%2FN%2B6oBIwSM9FP6TTk55bDxJ6&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216117s001lbl.pdf#page=25</a></p>
<p style="text-indent:-2em;margin-left:4em;">Ritalin: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F010187s092s096lbl.pdf%23page18&amp;token=n7SOdTU4aIy7eYFWDuse4pG2IYYr72zIx3Rk7%2BS%2F065r0CFPVD4QdCg2PJQfBwYHlOqiX%2F6Z9u3ju2d%2BuDa%2FdBnwHOqW8s37s6FJF4rKuyC6L5lL6j8njnUHQgjvU4%2Bl&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/010187s092s096lbl.pdf#page18</a></p>
<p style="text-indent:-2em;margin-left:4em;">Ritalin LA: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021284s042s046lbl.pdf%23page18&amp;token=NVaIun6VOsDbPx7OHyg7yLlGdaIfae8j%2Bx%2BU%2FDdrJ%2FHMDnl9ve%2FiYYdHHs5%2Ft%2FPPR0TC2U4DXWmZ%2FforDMQdQsfKkvA1%2BnyZfVxgaq%2FfkJfESRO7%2FKZ8xsTvJ0Pq5%2FdW&amp;TOPIC_ID=9638" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021284s042s046lbl.pdf#page18</a></p></div>
<div class="block use drugH1Div" id="F195274"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy (Methylin, Metadate ER, Ritalin, and Ritalin SR [Canadian product]):</b> Symptomatic management of narcolepsy.</p></div>
<div class="block off-label drugH1Div" id="F25469400"><span class="drugH1">Use: Off-Label: Adult</span><p>Fatigue, severe, cancer related or in palliative care setting; Major depressive disorder (unipolar) in medically ill, palliative care, terminal illness, or elderly patients</p></div>
<div class="block mst drugH1Div" id="F195336"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Metadate CD may be confused with Metadate ER</p>
<p style="text-indent:-2em;margin-left:4em;">Metadate ER may be confused with methadone</p>
<p style="text-indent:-2em;margin-left:4em;">Methylphenidate may be confused with methadone</p>
<p style="text-indent:-2em;margin-left:4em;">QuilliChew ER may be confused with Quillivant XR</p>
<p style="text-indent:-2em;margin-left:4em;">Ritalin may be confused with Rifadin</p>
<p style="text-indent:-2em;margin-left:4em;">Ritalin LA may be confused with Ritalin SR</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F195323"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F195265"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihypertensive Agents: Methylphenidate may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: May enhance the adverse/toxic effect of Dexmethylphenidate-Methylphenidate. Dexmethylphenidate-Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk of extrapyramidal symptoms may be increased when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Bromperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: May increase the serum concentration of Methylphenidate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of CNS Stimulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: Dexmethylphenidate-Methylphenidate may enhance the hypertensive effect of Inhalational Anesthetics. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: CNS Stimulants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Methylphenidate may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Methylphenidate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Methylphenidate may increase the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Methylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Methylphenidate may enhance the cardiotoxic effect of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Dexmethylphenidate-Methylphenidate may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F195292"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: Alcohol consumption increases the rate of methylphenidate release from ER capsules (eg, Adhansia XR, Jornay PM, methylphenidate ER capsule [generic Metadate CD], Ritalin LA) and QuilliChew ER (ER chewable tablet), but not from Concerta (ER tablet) or Relexxii (ER tablet); in vitro studies showed that an alcohol concentration of 40% resulted in 84%, and 98% of the methylphenidate being released in the first hour with methylphenidate ER capsule (generic Metadate CD) and Ritalin LA, respectively, and 97% of the methylphenidate being released in 2 hours with Jornay PM; a study involving Adhansia XR showed that an alcohol concentration of 40% resulted in 71% of a 70 mg dose and 61% of a 100 mg dose being released in the first 2 hours; a study involving QuilliChew ER showed that an alcohol concentration of 40% resulted in 90% of the methylphenidate being released in the first half hour. Management: Avoid consuming alcohol during therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Food: Food may increase oral absorption of IR tablet/solution/chewable tablet and Metadate ER. Management: Administer 30 to 45 minutes before meals.</p></div>
<div class="block pri drugH1Div" id="F195281"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of methylphenidate in pregnant women with attention-deficit/hyperactivity disorder (Ornoy 2018) or narcolepsy (Calvo-Ferrandiz 2018; Maurovich-Horvat 2013; Thorpy 2013) is limited and outcome data is conflicting (Ornoy 2018). If treatment of ADHD in pregnancy is needed, methylphenidate may be considered (Larsen 2015; McAllister-Williams 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to methylphenidate is ongoing. Health care providers are encouraged to enroll females exposed to methylphenidate during pregnancy in the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.</p></div>
<div class="block brc drugH1Div" id="F3277308"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of methylphenidate is 0.7% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 52 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of methylphenidate was calculated using a milk concentration of 19 mcg/L, providing an absolute daily infant dose via breast milk of 2.9 mcg/kg/day. This milk concentration was obtained following maternal administration methylphenidate to three women for ADHD. Maternal doses ranged from 35 to 80 mg/day (Hackett 2006). Authors of two additional case reports calculated the RID of methylphenidate &lt;1% (Hackett 2006; Spigset 2007). In a case report, methylphenidate was no longer detectable in breast milk 20 to 21 hours after the maternal dose following administration of the immediate release tablet (Spigset 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Adverse events were not noted in three case reports (Bolea-Alamanac 2014a; Hackett 2006; Spigset 2007); however, infants in two cases were older (6 months of age and 11 months of age) and exposure was limited (Hackett 2006; Spigset 2007). Long-term developmental effects have not been studied. Growth and medical development were normal in one child up to 1 year of age (Bolea-Alamanac 2014a).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Monitor breastfeeding infants for adverse reactions, such as agitation, anorexia, insomnia, and reduced weight gain.</p></div>
<div class="block dic drugH1Div" id="F195282"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer the short-acting IR tablet (Ritalin), IR solution (Methylin), and IR chewable tablet 30 to 45 minutes before meals. Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F195269"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count periodically with prolonged therapy. Cardiac evaluation (including medical or family history of sudden death or ventricular arrhythmia; ECG as indicated) should be completed at baseline and on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants. Monitor blood pressure and heart rate (baseline, following dose increases and periodically during treatment); growth rate (height and weight) and appetite in children; weight in adults; signs of peripheral vasculopathy (eg, digital changes); sleep and behavioral changes; assess family history and evaluate for tics or Tourette syndrome prior to initiation of therapy; assess for new signs or worsening of tics or Tourette syndrome during treatment; intraocular pressure (IOP) in patients with history of open angle glaucoma or increased IOP. Assess for risk of abuse prior to prescribing and signs of misuse, abuse, or substance use disorder throughout treatment (NICE 2018). Screen for bipolar disorder and risk factors for developing a manic episode prior to treatment; monitor for psychotic or manic symptoms (eg, delusional thinking, hallucinations, mania) or suicide-related behavior; in children monitor for development or worsening of aggressive behavior or hostility.</p>
<p style="text-indent:0em;margin-top:2em;">Transdermal: Signs of worsening erythema, blistering or edema which does not improve within 48 hours of patch removal, or spreads beyond patch site.</p></div>
<div class="block pha drugH1Div" id="F195259"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mild CNS stimulant; blocks the reuptake of norepinephrine and dopamine into presynaptic neurons; appears to stimulate the cerebral cortex and subcortical structures similar to amphetamines </p></div>
<div class="block phk drugH1Div" id="F195277"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action (AAP [Wolraich 2011]):</p>
<p style="text-indent:-2em;margin-left:4em;">Children:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">ER formulations (capsule [Metadate CD, Ritalin LA], tablets [Concerta]): 20 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:8em;">IR formulations (chewable tablet, oral solution, tablet [Methylin, Ritalin]): 20 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:8em;">Sustained-release tablet (Ritalin SR [Canadian product]): 60 to 180 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">Transdermal (Daytrana): 60 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral: Controlled-release: Foquest [Canadian product]: Within 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Maximum effect: Oral: IR tablet: Within 2 hours; Sustained-release tablet (Ritalin SR [Canadian product]): Within 4 to 7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Controlled-release capsule (Foquest [Canadian product]): 16 hours</p>
<p style="text-indent:-2em;margin-left:6em;">ER capsule: Metadate CD, Ritalin LA: 6 to 8 hours (AAP [Wolraich 2011]); Aptensio XR: ≤16 hours</p>
<p style="text-indent:-2em;margin-left:6em;">ER tablet (Concerta): 8 to 12 hours (AAP [Wolraich 2011]; Jain 2017)</p>
<p style="text-indent:-2em;margin-left:6em;">ER tablet (Metadate ER): 8 hours</p>
<p style="text-indent:-2em;margin-left:6em;">IR formulations (chewable tablet, oral solution, IR tablet [Methylin, Ritalin]): 3 to 5 hours (AAP [Wolraich 2011]; Jain 2017)</p>
<p style="text-indent:-2em;margin-left:6em;">Sustained-release tablet (Ritalin SR [Canadian product]): 2 to 8 hours (AAP [Wolraich 2011]; Jain 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal (Daytrana): 11 to 12 hours (AAP [Wolraich 2011])</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Readily absorbed</p>
<p style="text-indent:-2em;margin-left:6em;">Controlled-release capsule:</p>
<p style="text-indent:-2em;margin-left:8em;">Biphentin [Canadian product]: Food delayed initial peak slightly (~18 minutes); relative to immediate-release tablets, AUC is similar in fed or fasted state (~100%)</p>
<p style="text-indent:-2em;margin-left:8em;">Foquest [Canadian product]: Food does not significantly affect AUC and C<sub>max</sub></p>
<p style="text-indent:-2em;margin-left:6em;">ER capsule:</p>
<p style="text-indent:-2em;margin-left:8em;">Adhansia XR: A high fat meal increased the time to first and second C<sub>max</sub> by about 1 hour. When administered with a 40% alcohol concentration in fasted healthy adults, there was a 1.4-fold increase in the peak plasma methylphenidate concentration and a 1.3-fold increase in the extent of absorption; in vitro studies at an alcohol concentration of 40% also demonstrated faster release with 71% of a 70 mg dose and 61% of a 100 mg dose of methylphenidate released at hour 2.</p>
<p style="text-indent:-2em;margin-left:8em;">Aptensio XR: A high-fat meal increased C<sub>max</sub> (~28%) and AUC (~19%). At an alcohol concentration up to 40% there was 96% release of methylphenidate within 2 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Jornay PM: Initial absorption is delayed with ≤5% of total drug available within first 10 hours after dosing. A high-fat meal at night decreased C<sub>max</sub> (14%) and extended the median T<sub>max</sub> by ~2.5 hours; a high-fat morning meal had no effect on the pharmacokinetics. At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate, resulting in 97% of the methylphenidate being released in 2 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Methylphenidate ER capsules (generic Metadate CD): A high-fat meal delayed the early peak (~1 hour), and increased C<sub>max</sub> (~30%) and AUC (~17%). At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 84% of the methylphenidate being released.</p>
<p style="text-indent:-2em;margin-left:8em;">Ritalin LA: A high-fat meal delayed absorption and peak times, but not the amount absorbed nor initial peak concentration (second peak lowered by ~25%). At an alcohol concentration of 40%, there was a 98% release of methylphenidate in the first hour.</p>
<p style="text-indent:-2em;margin-left:6em;">ER chewable tablet: A high-fat meal increased C<sub>max</sub> (~20%) and AUC<sub>inf</sub> (~4%). At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first half hour, resulting in 90% of the methylphenidate being released.</p>
<p style="text-indent:-2em;margin-left:6em;">ER orally disintegrating tablet: Cotempla XR-ODT: A high-fat meal decreased C<sub>max</sub> (24%) and increased AUC<sub>inf </sub>(16%) and led to an earlier peak (~0.5 hour).</p>
<p style="text-indent:-2em;margin-left:6em;">ER suspension: Quillivant XR: A high-fat meal led to an earlier peak (~1 hour), and increased C<sub>max</sub> (~28%) and AUC (~19%).</p>
<p style="text-indent:-2em;margin-left:6em;">ER tablet: Metadate ER: Food resulted in greater C<sub>max</sub> and AUC compared to fasting.</p>
<p style="text-indent:-2em;margin-left:6em;">IR chewable tablet: A high-fat meal delayed peak time (~1 hour) and increased AUC (~20%).</p>
<p style="text-indent:-2em;margin-left:6em;">IR solution: Methylin: A high-fat meal delayed peak time (~1 hour), and increased C<sub>max</sub> (~13%) and AUC (~25%).</p>
<p style="text-indent:-2em;margin-left:6em;">IR tablet: A high-fat meal, increased the AUC (25%) and C<sub>max</sub> (27%).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: Absorption increased when applied to inflamed skin or exposed to heat. Absorption is continuous for 9 hours after application.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: <i>d</i>-methylphenidate: 2.65 ± 1.11 L/kg, <i>l</i>-methylphenidate: 1.80 ± 0.91 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 10% to 33%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive metabolism, predominately via de-esterification by carboxylesterase CES1A1 to alpha-phenyl-piperidine acetic acid (PPAA; ritalinic acid) which has little to no pharmacologic activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule:</p>
<p style="text-indent:-2em;margin-left:6em;">Aptensio XR: 102% (relative to IR oral product)</p>
<p style="text-indent:-2em;margin-left:6em;">Jornay PM: 73.9% (relative to IR oral product)</p>
<p style="text-indent:-2em;margin-left:4em;">ER suspension: Quillivant XR: 95% (relative to IR oral solution)</p>
<p style="text-indent:-2em;margin-left:4em;">IR chewable tablets and oral solution: Bioequivalent to IR tablets</p>
<p style="text-indent:-2em;margin-left:4em;">Sustained-release tablet (Ritalin SR [Canadian product]): 105% (49% to 168%) in children and 101% (85% to 152%) in adults (relative to IR oral product)</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch (Daytrana): Lower first-pass effect compared to oral administration; thus, much lower doses (on a mg/kg basis) given via the transdermal route may still produce higher AUCs, compared to the oral route</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Controlled-release capsule: Biphentin [Canadian product]: Children: 2.4 hours; Adults: 2.1 hours; Foquest [Canadian product]: Adults: 6.95 ± 3.25 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule:</p>
<p style="text-indent:-2em;margin-left:6em;">Adhansia XR:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 12 years of age: ~4 to 7 hours</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≤17 years of age: ~5 hours</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 7 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Aptensio XR: Adults: ~5 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Jornay PM: Adults: ~5.9 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Methylphenidate ER capsules (generic Metadate CD): Adults: 6.8 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Ritalin LA: Children: 1.5 to 4 hours; Adults: 3 to 4.2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ER chewable tablets: ~5.2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ER orally disintegrating tablet: 4 to 4.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ER suspension: Quillivant XR: Children ≥9 years of age, Adolescents, and Adults: ~5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Concerta, Relexxii: Adolescents and Adults: ~3.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IR chewable tablet: Adults: 3 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IR solution: Methylin: Adults: 2.7 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Children: 3.5 hours (1.5 to 5 hours)</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 3.5 hours (1.3 to 7.7 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: Children and Adolescents 6 to 17 years of age: <i>d</i>-methylphenidate ~4 to 5 hours, <i>l</i>-methylphenidate 1.4 to 2.9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Controlled-release capsule:</p>
<p style="text-indent:-2em;margin-left:6em;">Biphentin [Canadian product]: Children: Initial: ~2.5 hours; Adults: Initial: ~2 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Foquest [Canadian product]: Children: Initial peak between 1.5 to 2.0 hours followed by a second peak between 9 to 11 hours; Adults: Initial peak at ~1.6 hours followed by second peak at ~12.5 hours (range: 11 to 16 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule:</p>
<p style="text-indent:-2em;margin-left:6em;">Adhansia XR:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 12 years of age: Initial: 2 hours (range: 1 to 4 hours); Second peak: 10 hours (8 to 14 hours)</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≤17 years of age: Initial: 2 hours (range: 1 to 4 hours); Second peak: 11 hours (8 to 14 hours)</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: Initial: 1.5 hours (range: 1 to 2.5 hours); Second peak: ~12 hours (range: 8.5 to 16 hours)</p>
<p style="text-indent:-2em;margin-left:6em;">Aptensio XR: Adults: Initial: ~2 hours; Second peak: ~8 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Jornay PM: Adults: 14 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Methylphenidate ER capsule (generic Metadate CD): Children: Initial: ~1.5 hours; Second peak: ~4.5 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Ritalin LA:</p>
<p style="text-indent:-2em;margin-left:8em;">Children: Initial: 1 to 3 hours; Second peak: 5 to 11 hour</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: Initial: 1.3 to 4 hours; Second peak: 4.3 to 6.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ER chewable tablet: QuilliChew ER: Adults: 5 hours (median)</p>
<p style="text-indent:-2em;margin-left:4em;">ER orally disintegrating tablet: Cotempla XR-ODT: ~5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">ER suspension: Quillivant XR: Children (9 to 12 years of age): 4.05 hours (range: 3.98 to 6 hours); Adolescents (13 to 15 years of age): 2 hours (range: 1.98 to 4 hours); Adults: 4 hours (range: 1.3 to 7.3 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Concerta: Initial: ~1 hours, followed by gradually ascending concentrations over 5 to 9 hours; Mean peak: 6 to 10 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Relexxii: Initial: ~1.5 hours, followed by a second peak around 5.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IR chewable tablet: ~1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IR solution: Methylin: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: Children: 1.9 hours (range: 0.3 to 4.4 hours); time to peak is faster after a high-fat meal as compared to without food (median T<sub>max</sub>: 2.5 hours versus 3 hours, respectively).</p>
<p style="text-indent:-2em;margin-left:4em;">Sustained-release tablet (Ritalin SR [Canadian product]): Children: 4.7 hours (range: 1.3 to 8.2 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: ~8 to 10 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (78% to 97% as metabolites and unchanged drug); Feces (1% to 3%)</p></div>
<div class="block phksp drugH1Div" id="F51159497"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric:</p>
<p style="text-indent:-2em;margin-left:4em;">ER capsule: Ritalin LA: Time until the between peak minimum and the time until the second peak were delayed and more variable in children 10 to 12 years of age compared to adults. After a 20 mg dose, concentrations in children were approximately twice the concentrations observed in adults 18 to 35 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">ER suspension: Quillivant XR: After a single oral dose of 60 mg plasma concentrations of methylphenidate in children (9 to 12 years of age) were approximately twice the concentrations observed in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: The C<sub>max</sub> and AUC of <i>d</i>-methylphenidate were ~50% lower in adolescents, compared to children, following either a 1-day or 7-day administration of 10 mg/9 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F195283"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ritaline</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Methylin | Mfd | Ritalina | Rubifen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Medikinet | Methylphenidat stada | Ritalin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Artige | Attenta | Cm methylphenidate | Concerta | Lorentin | Methylphenidate | Methylphenidate sandoz xr | Methylphenidate teva xr | Methylphenidate xr arx | Ritalin | Ritalin la | Rubifen la | Tw methylphenidate</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Methyphen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Equasym | Medikinet | Rilatine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Attenze | Cloridrato de metilfenidato | Medato | Ritalina | Tedeaga</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Equasym | Medikinet | Medikinet mr | Methylphenidat Mepha LA | Ritalin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aradix | Elem | Metrans | Minfel | Nebapul | Ritalin | Ritrocel | Rubifen</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Li tai lin | Methylphenidate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Ritalina | Rubifen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Equasym | Medikinet | Medikinet adult | Medikinet Retard | Methylpheni tad | Methylphenidat 1 a pharma | Methylphenidat al | Methylphenidat Hexal | Methylphenidat ratiopharm | Methysym | Ritalin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Motiron | Ritalin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Medikinet | Medikinet Retard | Ritalina | Rubifen | Tradea</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Consiv | Ritalina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Affenid | Medikinet | Medikinet Xl | Ritalin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Equasym | Medicebran | Medikinet | Methysym retard | Rubifen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Medikinet | Ritalin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Medikinet | Methylphenidat arrow | Quasym l.p. | Ritaline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Delmosart | Equasym | Medikinet | Medikinet Xl | Methylphenidat | Methylphenidate | Metyrol xl | Ritalin | Tranquilyn</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ritalin | Ritaline</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Methylphenidate | Pms methylphenidate | Ritalin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Centedrin | Ritalin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Methyl phenidate | Methylphenidate | Prohiper | Ritalin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Equasym | Medikinet | Medikinet Xl | Ritalin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Ritalin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Addwize | Inspiral</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Equasym | Medikinet</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Medikinet Retard</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Methylphenidate hcl douglas | Metphen | Ritalin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biphentin | Bisphentin cr | Medikinet Retard | Meperine | Metadate CD | Methylpen | Penid | Perospin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ritaline</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Centedrin | Medikinet | Medikinet Xl | Ritalin | Rubifen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Equasym | Medikinet | Rilatine | Ritalin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Centedrin | Medikinet | Medikinet Xl | Ritalin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Butronin | Guardax | Metadate CD | Metilfenidato | Pisafical | Ritalin | Ritalin la | Ritalin sr | Tradea | Tradea lp</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-methylphenidate | Medikinet mr | Ritalin | Rubifen</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Equasym | Kinecteen | Medikinet | Methylfenidaat hcl | Methylfenidaat hcl centrafarm | Methylfenidaat Hcl Gf | Methylfenidaat hcl sandoz | Methylfenidaat hcl xiromed | Methylfenidaathydrochloride PCH | Ritalin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Equasym | Medikinet | Metylfenidat aurora medical | Ritalin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Methylphenidate | Ritalin | Rubifen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aradix | Consiv | Ritalin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Methylphenidate | Ritalin | Ritalin la</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Phenida | Ritalin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Ritalin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adhansia xr | Aptensio xr | Concerta | Jornay pm | Metadate cd cd ii extended release | Methylin | Methylin er | Methylphenidate | Methylphenidate HCL | Quillichew er | Quillivant xr | Ritalin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Metilfenidato ciclum | Metilfenidato Farmoz | Metilfenidato mylan | Metilfenidato ratiopharm | Ritalina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cognil | Metilfenidato bilac | Ritalina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Concerta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ritaline</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Affenid | Concerta | Equasym | Equasym depot | Medanef | Medikinet | Methylphenidat alternova | Methylphenidate 2care4 | Methylphenidate xiromed | Metylfenidat teva | Metynor | Ritalin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Ritalin | Rubifen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Medikinet | Metylfenidat neuraxpharm | Ritalin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Concerta | Methylphenidate | Ritalin la | Ritarin | Rubifen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ritaline</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Istimil | Medikinet | Medikinet Retard | Ritaline</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo-Methylphenidat | Methydur | Ritalin | Toncus</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ritalina | Rubifen</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acerta | Adaphen | Concerta | Contramyl xr | Medikinet mr | Methylphenidate | Methylphenidate unicorn | Radd | Ritalin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ritalin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Adhansia XR (methylphenidate) extended-release capsules [prescribing information]. Wilson, NC: Purdue Pharmaceuticals L.P.; June 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ahlfors.1">
<a name="Ahlfors.1"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11581465">
<a name="11581465"></a>American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder, “Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder,” <i>Pediatrics</i>, 2001, 108(4):1033-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/11581465/pubmed" id="11581465" target="_blank">11581465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroon.com/index.php?s=43&amp;item=422.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32726522">
<a name="32726522"></a>Andrade C. Methylphenidate and the risk of new-onset seizures. <i>J Clin Psychiatry</i>. 2020;81(4):20f13586. doi:10.4088/JCP.20f13586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/32726522/pubmed" id="32726522" target="_blank">32726522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patheon.1">
<a name="Patheon.1"></a>Aptensio XR (methylphenidate) extended-release capsules [prescribing information]. Wilson, NC: Rhodes Pharmaceuticals; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29359460">
<a name="29359460"></a>Ardic UA, Ercan ES. Resolution of methylphenidate osmotic release oral system-induced hair loss in two siblings after dose escalation. <i>Pediatr Int</i>. 2017;59(11):1217-1218. doi:10.1111/ped.13414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/29359460/pubmed" id="29359460" target="_blank">29359460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17974748">
<a name="17974748"></a>Arnold LE, Lindsay RL, López FA, et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. <i>Pediatrics.</i> 2007;120(5):1100-1106. doi: 10.1542/peds.2007-0542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17974748/pubmed" id="17974748" target="_blank">17974748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2651850">
<a name="2651850"></a>Baños JE, Bosch F, Farré M. Drug-induced priapism. Its aetiology, incidence and treatment. <i>Med Toxicol Adverse Drug Exp</i>. 1989;4(1):46-58. doi:10.1007/BF03259902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/2651850/pubmed" id="2651850" target="_blank">2651850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16987156">
<a name="16987156"></a>Billiard M, Bassetti C, Dauvilliers Y, et al; EFNS Task Force. EFNS guidelines on management of narcolepsy. <i>Eur J Neurol</i>. 2006;13(10):1035-1048. doi: 10.1111/j.1468-1331.2006.01473.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/16987156/pubmed" id="16987156" target="_blank">16987156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elvium.1">
<a name="Elvium.1"></a>Biphentin (methylphenidate) [product monograph]. Toronto, Ontario, Canada: Elvium Life Sciences; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23593966">
<a name="23593966"></a>Bolea-Alamanac BM, Green A, Verma G, Maxwell P, Davies SJ. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. <i>Br J Clin Pharmacol</i>. 2014a;77(1):96-101. doi: 10.1111/bcp.1213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23593966/pubmed" id="23593966" target="_blank">23593966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24526134">
<a name="24526134"></a>Bolea-Alamañac B, Nutt DJ, Adamou M, et al; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. <i>J</i>
<i>Psychopharmacol</i>. 2014b;28(3):179-203. doi: 10.1177/0269881113519509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24526134/pubmed" id="24526134" target="_blank">24526134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2891464">
<a name="2891464"></a>Bond WS, “Recognition and Treatment of Attention Deficit Disorder,” <i>Clin Pharm</i>, 1987, 6(8):617-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/2891464/pubmed" id="2891464" target="_blank">2891464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24733803">
<a name="24733803"></a>Bower JE, Bak K, Berger A, et al; American Society of Clinical Oncology. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation.<i> J Clin Oncol</i>. 2014;32(17):1840-1850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24733803/pubmed" id="24733803" target="_blank">24733803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bukstein.1">
<a name="Bukstein.1"></a>Brent D, Bukstein O, Solanto MV. Attention deficit hyperactivity disorder in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bruera.1">
<a name="Bruera.1"></a>Bruera E, Dev R. Overview of fatigue, weakness, and asthenia in palliative care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21043394">
<a name="21043394"></a>Cakin-Memik N, Yildiz O, Sişmanlar SG, Karakaya I, Ağaoğlu B. Priapism associated with methylphenidate: a case report. <i>Turk J Pediatr</i>. 2010;52(4):430-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/21043394/pubmed" id="21043394" target="_blank">21043394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28568319">
<a name="28568319"></a>Calvo-Ferrandiz E, Peraita-Adrados R. Narcolepsy with cataplexy and pregnancy: a case-control study. <i>J Sleep Res</i>. 2018;27(2):268-272. doi: 10.1111/jsr.12567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28568319/pubmed" id="28568319" target="_blank">28568319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30932948">
<a name="30932948"></a>Chandradasa M, Rathnayake LC. Immediate-release methylphenidate-associated recurrent nasal bleeding in siblings. <i>J Clin Psychopharmacol</i>. 2019;39(3):284-285. doi:10.1097/JCP.0000000000001033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/30932948/pubmed" id="30932948" target="_blank">30932948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27745746">
<a name="27745746"></a>Cheng C, La Grenade L, Diak IL, Brinker A, Levin RL. Chemical leukoderma associated with methylphenidate transdermal system: data from the US Food and Drug Administration adverse event reporting system. <i>J Pediatr</i>. 2017;180:241-246. doi:10.1016/j.jpeds.2016.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/27745746/pubmed" id="27745746" target="_blank">27745746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33892111">
<a name="33892111"></a>Childress AC, Foehl HC, Newcorn JH, Faraone SV, Levinson B, Adjei AL. Long-term treatment with extended-release methylphenidate treatment in children aged 4 to &lt;6 years. <i>J Am Acad Child Adolesc Psychiatry</i>. 2022;61(1):80-92. doi:10.1016/j.jaac.2021.03.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/33892111/pubmed" id="33892111" target="_blank">33892111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32125903">
<a name="32125903"></a>Childress AC, Kollins SH, Foehl HC, et al. Randomized, double-blind, placebo-controlled, flexible-dose titration study of methylphenidate hydrochloride extended-release capsules (Aptensio XR) in preschool children with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol</i>. 2020;30(2):58-68. doi:10.1089/cap.2019.0085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/32125903/pubmed" id="32125903" target="_blank">32125903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31135892">
<a name="31135892"></a>Ching C, Eslick GD, Poulton AS. Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis [published online May 28, 2019]. <i>JAMA Pediatr</i>. doi: 10.1001/jamapediatrics.2019.0905.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/31135892/pubmed" id="31135892" target="_blank">31135892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1477441">
<a name="1477441"></a>Cohen HA, Ashkenazi A, Nussinovitch M, Gross S, Frydman M. Fixed drug eruption of the scrotum due to methylphenidate. <i>Ann Pharmacother</i>. 1992;26(11):1378-1379. doi:10.1177/106002809202601107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/1477441/pubmed" id="1477441" target="_blank">1477441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.1">
<a name="Janssen.1"></a>Concerta (methylphenidate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.1">
<a name="Janssen.1"></a>Concerta (methylphenidate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.2">
<a name="Janssen.2"></a>Concerta (methylphenidate) [product monograph]. Toronto, Ontario, Canada: Elvium Life Sciences; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22043968">
<a name="22043968"></a>Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. <i>N Engl J Med.</i> 2011;365(20):1896-1904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22043968/pubmed" id="22043968" target="_blank">22043968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30097390">
<a name="30097390"></a>Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i>. 2018;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/30097390/pubmed" id="30097390" target="_blank">30097390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23294014">
<a name="23294014"></a>Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. <i>J Child Psychol Psychiatry</i>. 2013;54(3):227-246. doi: 10.1111/jcpp.12036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23294014/pubmed" id="23294014" target="_blank">23294014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neos.1">
<a name="Neos.1"></a>Cotempla XR-ODT (methylphenidate) [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26485338">
<a name="26485338"></a>Cressman AM, Macdonald EM, Huang A, et al; Canadian Drug Safety and Effectiveness Research Network. Prescription stimulant use and hospitalization for psychosis or mania: A population-based study. <i>J Clin Psychopharmacol</i>. 2015;35(6):667-671. doi:10.1097/JCP.0000000000000406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/26485338/pubmed" id="26485338" target="_blank">26485338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1681750">
<a name="1681750"></a>Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. <i>Am J Psychiatry</i>. 1991;148(11):1474-1486. doi:10.1176/ajp.148.11.1474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/1681750/pubmed" id="1681750" target="_blank">1681750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21733284">
<a name="21733284"></a>Davis C, Fattore L, Kaplan AS, Carter JC, Levitan RD, Kennedy JL. The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. <i>Int J Neuropsychopharmacol</i>. 2012;15(2):181-187. doi:10.1017/S1461145711001039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/21733284/pubmed" id="21733284" target="_blank">21733284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Noven.1">
<a name="Noven.1"></a>Daytrana (methylphenidate) transdermal system [prescribing information]. Miami, FL: Noven Therapeutics LLC; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24982313">
<a name="24982313"></a>Eiland LS, Bell EA, Erramouspe J. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. <i>Ann Pharmacother</i>. 2014;48(10):1350-1355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24982313/pubmed" id="24982313" target="_blank">24982313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21894543">
<a name="21894543"></a>Ensat F, Edelbauer M, Wechselberger G. Unilateral gynecomastia in a prepubertal boy. <i>Eur J Pediatr</i>. 2012;171(1):197. doi:10.1007/s00431-011-1546-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/21894543/pubmed" id="21894543" target="_blank">21894543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28301399">
<a name="28301399"></a>Ercan ES, Inci SB, Ipci M. Is there an effect of methylphenidate on thrombocytopenia? <i>J Clin Psychopharmacol</i>. 2017;37(3):374. doi:10.1097/JCP.0000000000000690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28301399/pubmed" id="28301399" target="_blank">28301399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Safety Alert. Daytrana Patch (methylphenidate). Food and Drug Administration website. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm452244.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm452244.htm</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35695715">
<a name="35695715"></a>Ferahkaya H, Uzun N. Methylphenidate-associated syncope: a case report. <i>J Clin Psychopharmacol</i>. 2022;42(4):419-420. doi:10.1097/JCP.0000000000001567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/35695715/pubmed" id="35695715" target="_blank">35695715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19808143">
<a name="19808143"></a>Findling RL, Wigal SB, Bukstein OG, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. <i>Clin Ther</i>. 2009;31(8):1844-1855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/19808143/pubmed" id="19808143" target="_blank">19808143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns of rare risk of long-lasting erections in males taking methylphenidate ADHD medications and has approved label changes. <a href="https://www.fda.gov/drugs/drugsafety/ucm375796.htm" target="_blank">https://www.fda.gov/drugs/drugsafety/ucm375796.htm</a>. Published December 17, 2013. Accessed September 27, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elvium.2">
<a name="Elvium.2"></a>Foquest (methylphenidate) [product monograph]. Toronto, Ontario, Canada: Elvium Life Sciences; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25492713">
<a name="25492713"></a>Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/25492713/pubmed" id="25492713" target="_blank">25492713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18844482">
<a name="18844482"></a>Ghuman JK, Arnold LE, and Anthony BJ, "Psychopharmacological and Other Treatments in Preschool Children With Attention-Deficit/Hyperactivity Disorder: Current Evidence and Practice," <i>J Child Adolesc Psychopharmacol</i>, 2008, 18(5):413-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18844482/pubmed" id="18844482" target="_blank">18844482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18030077">
<a name="18030077"></a>Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(12):1532-1572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18030077/pubmed" id="18030077" target="_blank">18030077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18240233">
<a name="18240233"></a>Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients. <i>Arthritis Rheum</i>. 2008;58(2):563-566. doi:10.1002/art.23301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18240233/pubmed" id="18240233" target="_blank">18240233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19528194">
<a name="19528194"></a>Gould MS, Walsh BT, Munfakh JL, et al, "Sudden Death and Use of Stimulant Medications in Youths," <i>Am J Psychiatry</i>, 2009, 166(9):992-1001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/19528194/pubmed" id="19528194" target="_blank">19528194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25265450">
<a name="25265450"></a>Goyal R, Arroyave A, Malik S. Urticaria and angioedema secondary to methylphenidate exposure in a young child. <i>J Child Adolesc Psychopharmacol</i>. 2015;25(9):731-733. doi:10.1089/cap.2014.0040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/25265450/pubmed" id="25265450" target="_blank">25265450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17023869">
<a name="17023869"></a>Greenhill L, Kollins S, Abikoff H, et al, "Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD," <i>J Am Acad Child Adolesc Psychiatry</i>, 2006, 45(11):1284-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17023869/pubmed" id="17023869" target="_blank">17023869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1347936">
<a name="1347936"></a>Greenhill LL, “Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder,” <i>Psychiatr Clin North Am</i>, 1992, 15(1):1-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/1347936/pubmed" id="1347936" target="_blank">1347936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31421233">
<a name="31421233"></a>Greenhill LL, Swanson JM, Hechtman L, et al; MTA Cooperative Group. Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-eeficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(8):978-989. doi:10.1016/j.jaac.2019.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/31421233/pubmed" id="31421233" target="_blank">31421233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4038730">
<a name="4038730"></a>Grossman LK, Grossman NJ. Methylphenidate and idiopathic thrombocytopenic purpura--is there an association? <i>J Fam Pract</i>. 1985;20(3):302-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/4038730/pubmed" id="4038730" target="_blank">4038730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22161946">
<a name="22161946"></a>Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. <i>JAMA</i>. 2011;306(24):2673-2683. doi:10.1001/jama.2011.1830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22161946/pubmed" id="22161946" target="_blank">22161946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16940409">
<a name="16940409"></a>Hackett LP, Kristensen JH, Hale TW, et al, “Methylphenidate and Breast-Feeding,” <i>Ann Pharmacother</i>, 2006, 40(10):1890-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/16940409/pubmed" id="16940409" target="_blank">16940409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19281939">
<a name="19281939"></a>Hardy SE. Methylphenidate for treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. <i>Am J Geriatr Pharmacother</i>. 2009;7(1):34-59. doi: 10.1016/j.amjopharm.2009.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/19281939/pubmed" id="19281939" target="_blank">19281939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25180281">
<a name="25180281"></a>Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. <i>Pediatrics</i>. 2014;134(4):e935-944. doi:10.1542/peds.2014-0428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/25180281/pubmed" id="25180281" target="_blank">25180281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31221557">
<a name="31221557"></a>Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. <i>Lancet Psychiatry</i>. 2019;6(8):651-658. doi:10.1016/S2215-0366(19)30189-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/31221557/pubmed" id="31221557" target="_blank">31221557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11712722">
<a name="11712722"></a>Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. <i>Am J Hosp Palliat Care</i>. 2001;18(6):403-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/11712722/pubmed" id="11712722" target="_blank">11712722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26398435">
<a name="26398435"></a>Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents. <i>J Pediatr Orthop</i>. 2017;37(5):348-354. doi:10.1097/BPO.0000000000000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/26398435/pubmed" id="26398435" target="_blank">26398435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22474070">
<a name="22474070"></a>Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. <i>Arch Gen Psychiatry</i>. 2012;69(8):776-786. doi:10.1001/archgenpsychiatry.2012.169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22474070/pubmed" id="22474070" target="_blank">22474070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29501070">
<a name="29501070"></a>Huang KL, Wei HT, Hsu JW, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. <i>Br J Psychiatry</i>. 2018;212(4):234-238. doi:10.1192/bjp.2018.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/29501070/pubmed" id="29501070" target="_blank">29501070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28740389">
<a name="28740389"></a>Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V. Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. <i>Neuropsychiatr Dis Treat</i>. 2017;13:1741-1751. doi: 10.2147/NDT.S130444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28740389/pubmed" id="28740389" target="_blank">28740389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28906602">
<a name="28906602"></a>Jain R, Jain S, Montano CB. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. <i>Prim Care Companion CNS Disord. </i>2017;19(5). pii: 17nr02153. doi: 10.4088/PCC.17nr02153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28906602/pubmed" id="28906602" target="_blank">28906602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ironshore.1">
<a name="Ironshore.1"></a>Jornay PM (methylphenidate) [prescribing information]. Morrisville, NC: Ironshore Pharmaceuticals Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22208450">
<a name="22208450"></a>Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. <i>J Pain Symptom Manage</i>. 2012;43(1):68-77. doi: 10.1016/j.jpainsymman.2011.03.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22208450/pubmed" id="22208450" target="_blank">22208450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3058088">
<a name="3058088"></a>Klein RG, Landa B, Mattes JA, Klein DF. Methylphenidate and growth in hyperactive children. A controlled withdrawal study. <i>Arch Gen Psychiatry</i>. 1988;45(12):1127-1130. doi:10.1001/archpsyc.1988.01800360075011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/3058088/pubmed" id="3058088" target="_blank">3058088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473984">
<a name="16473984"></a>Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 3rd. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. <i>Am J Geriatr Psychiatry</i>. 2006;14(2):181-185. doi: 10.1097/01.JGP.0000192503.10692.9f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/16473984/pubmed" id="16473984" target="_blank">16473984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677354">
<a name="25677354"></a>Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. <i>Am J Psychiatry</i>. 2015;172(6):561-569. doi: 10.1176/appi.ajp.2014.14070889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/25677354/pubmed" id="25677354" target="_blank">25677354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14981214">
<a name="14981214"></a>Leddy JJ, Epstein LH, Jaroni JL, et al. Influence of methylphenidate on eating in obese men. <i>Obes Res</i>. 2004;12(2):224-232. doi:10.1038/oby.2004.29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/14981214/pubmed" id="14981214" target="_blank">14981214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17219064">
<a name="17219064"></a>Lewis JJ, Iezzoni JC, Berg CL. Methylphenidate-induced autoimmune hepatitis. <i>Dig Dis Sci</i>. 2007;52(2):594-597. doi:10.1007/s10620-006-9525-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17219064/pubmed" id="17219064" target="_blank">17219064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26719291">
<a name="26719291"></a>MacKenzie LE, Abidi S, Fisher HL, et al. Stimulant medication and psychotic symptoms in offspring of parents with mental illness. <i>Pediatrics</i>. 2016;137(1). doi:10.1542/peds.2015-2486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/26719291/pubmed" id="26719291" target="_blank">26719291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28746699">
<a name="28746699"></a>Man KKC, Coghill D, Chan EW, et al. Association of risk of suicide attempts with methylphenidate treatment. <i>JAMA Psychiatry</i>. 2017;74(10):1048-1055. doi:10.1001/jamapsychiatry.2017.2183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28746699/pubmed" id="28746699" target="_blank">28746699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20410322">
<a name="20410322"></a>Marchant BK, Reimherr FW, Robison RJ, Olsen JL, Kondo DG. Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. <i>J Atten Disord</i>. 2011;15(4):295-304. doi: 10.1177/1087054710365986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/20410322/pubmed" id="20410322" target="_blank">20410322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160939">
<a name="23160939"></a>Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. <i>CNS Drugs</i>. 2013;27(1):15-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23160939/pubmed" id="23160939" target="_blank">23160939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23560595">
<a name="23560595"></a>Maurovich-Horvat E, Kemlink D, Högl B, et al, "Narcolepsy and Pregnancy: A Retrospective European Evaluation of 249 Pregnancies," <i>J Sleep Res</i>, 2013, doi: 10.1111/jsr.12047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23560595/pubmed" id="23560595" target="_blank">23560595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440103">
<a name="28440103"></a>McAllister-Williams RH, Baldwin DS, Cantwell R, et al; endorsed by the British Association for Psychopharmacology. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>J Psychopharmacol</i>. 2017;31(5):519-552. doi: 10.1177/0269881117699361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28440103/pubmed" id="28440103" target="_blank">28440103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20538968">
<a name="20538968"></a>McRae-Clark AL, Brady KT, Hartwell KJ, White K, Carter RE. Methylphenidate transdermal system in adults with past stimulant misuse: an open-label trial. <i>J Atten Disord</i>. 2011;15(7):539-544. doi: 10.1177/1087054710371171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/20538968/pubmed" id="20538968" target="_blank">20538968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Metadate CD (methylphenidate) [prescribing information]. Philadelphia, PA: Lannett Company Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UCB.1">
<a name="UCB.1"></a>Metadate ER (methylphenidate) [prescribing information]. Smyrna, GA: UCB, Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shionogi.1">
<a name="Shionogi.1"></a>Methylin oral solution [prescribing information]. Florham Park, NJ: Shionogi Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Camber.1">
<a name="Camber.1"></a>Methylphenidate chewable tablets [prescribing information]. Piscataway, NJ: Camber Pharmaceuticals Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Methylphenidate.3">
<a name="Methylphenidate.3"></a>Methylphenidate extended-release capsule [prescribing information]. Webster Groves, MO: SpecGx LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alvogen.1">
<a name="Alvogen.1"></a>Methylphenidate extended-release tablets (methylphenidate) [prescribing information]. Pine Brook, NJ: Alvogen, Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3704451">
<a name="3704451"></a>Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. <i>Sleep</i>. 1986;9(1, pt 2):260-264. doi: 10.1093/sleep/9.1.260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/3704451/pubmed" id="3704451" target="_blank">3704451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30893533">
<a name="30893533"></a>Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. <i>N Engl J Med</i>. 2019;380(12):1128-1138. doi:10.1056/NEJMoa1813751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/30893533/pubmed" id="30893533" target="_blank">30893533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19171629">
<a name="19171629"></a>Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. <i>Pediatrics</i>. 2009;123(2):611-616. doi:10.1542/peds.2008-0185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/19171629/pubmed" id="19171629" target="_blank">19171629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. London, UK: National Institute for Health and Care Excellence; March 2018. https://www.nice.org.uk/guidance/ng87. Accessed October 25, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549404">
<a name="16549404"></a>Nissen SE. ADHD drugs and cardiovascular risk. <i>N Engl J Med</i>. 2006 Apr 6;354(14):1445-1448. doi:10.1056/NEJMp068049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/16549404/pubmed" id="16549404" target="_blank">16549404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18561524">
<a name="18561524"></a>Nymark TB, Hovland A, Bjørnstad H, Nielsen EW. A young man with acute dilated cardiomyopathy associated with methylphenidate. <i>Vasc Health Risk Manag</i>. 2008;4(2):477-479. doi:10.2147/vhrm.s2410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18561524/pubmed" id="18561524" target="_blank">18561524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29411149">
<a name="29411149"></a>Ornoy A. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. <i>Pharm Res</i>. 2018;35(3):46. doi: 10.1007/s11095-017-2323-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/29411149/pubmed" id="29411149" target="_blank">29411149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36817810">
<a name="36817810"></a>Özdağ V, Koyuncu O, Özdemir YE, Tanir Y. Methylphenidate-induced menorrhagia in twin girls. <i>Iran J Psychiatry</i>. 2022;17(4):476-479. doi:10.18502/ijps.v17i4.10698<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/36817810/pubmed" id="36817810" target="_blank">36817810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11389303">
<a name="11389303"></a>Pelham WE, Gnagy EM, Burrows-Maclean L, et al, “Once-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings,” <i>Pediatrics</i>, 2001, 107(6), http://www.pediatrics.org/cgi/content/full/107/6/e105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/11389303/pubmed" id="11389303" target="_blank">11389303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):894-921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26544899">
<a name="26544899"></a>Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. <i>Int Clin Psychopharmacol</i>. 2016;31(2):93-99. doi:10.1097/YIC.0000000000000109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/26544899/pubmed" id="26544899" target="_blank">26544899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tris.1">
<a name="Tris.1"></a>QuilliChew ER (methylphenidate) extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tris.3">
<a name="Tris.3"></a>QuilliChew ER (methylphenidate) extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tris.2">
<a name="Tris.2"></a>Quillivant XR (methylphenidate) [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tris.4">
<a name="Tris.4"></a>Quillivant XR (methylphenidate) [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vertical.1">
<a name="Vertical.1"></a>Relexxii (methylphenidate hydrochloride) extended-release tablets [prescribing information]. Alpharetta, GA: Vertical Pharmaceuticals LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vertical.2">
<a name="Vertical.2"></a>Relexxii (methylphenidate hydrochloride) extended-release tablets [prescribing information]. Alpharetta, GA: Vertical Pharmaceuticals LLC; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24684534">
<a name="24684534"></a>Richard PO, Fleshner NE, Bhatt JR, Hersey KM, Chahin R, Alibhai SM. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. <i>BJU Int</i>. 2015;116(5):744-752. doi: 10.1111/bju.12755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24684534/pubmed" id="24684534" target="_blank">24684534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.4">
<a name="Novartis.4"></a>Ritalin (methylphenidate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.3">
<a name="Novartis.3"></a>Ritalin LA (methylphenidate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.5">
<a name="Novartis.5"></a>Ritalin LA (methylphenidate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.1">
<a name="Novartis.1"></a>Ritalin/Ritalin SR (methylphenidate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.2">
<a name="Novartis.2"></a>Ritalin/Ritalin SR (methylphenidate) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24874348">
<a name="24874348"></a>Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB. Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. <i>J Atten Disord</i>. 2017;21(14):1180-1191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24874348/pubmed" id="24874348" target="_blank">24874348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20665492">
<a name="20665492"></a>Roth AJ, Nelson C, Rosenfeld B, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. <i>Cancer</i>. 2010;116(21):5102-5110. doi: 10.1002/cncr.25424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/20665492/pubmed" id="20665492" target="_blank">20665492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy.1">
<a name="Roy.1"></a>Roy-Byrne PP. Management of psychiatric disorders in patients with cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31135823">
<a name="31135823"></a>Russell D, Weiss M, Stein MA. A Maximum Dose for Methylphenidate-How Much Is Too Much? [published online May 28, 2019]. <i>JAMA Pediatr</i>. doi: 10.1001/jamapediatrics.2019.0911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/31135823/pubmed" id="31135823" target="_blank">31135823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Scammell.1">
<a name="Scammell.1"></a>Scammell TE. Treatment of narcolepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22318795">
<a name="22318795"></a>Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. <i>Am J Psychiatry</i>. 2012;169(2):178-185. doi:10.1176/appi.ajp.2011.11010125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22318795/pubmed" id="22318795" target="_blank">22318795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27245699">
<a name="27245699"></a>Shin JY, Roughead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. <i>BMJ</i>. 2016;353:i2550. doi: 10.1136/bmj.i2550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/27245699/pubmed" id="27245699" target="_blank">27245699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9685453">
<a name="9685453"></a>Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. <i>Pediatrics</i>. 1998;102(2 Pt 3):501-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/9685453/pubmed" id="9685453" target="_blank">9685453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17267805">
<a name="17267805"></a>Spigset O, Brede WR, and Zahlsen K, “Excretion of Methylphenidate in Breast Milk,” <i>Am J Psychiatry</i>, 2007, 164(2):348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17267805/pubmed" id="17267805" target="_blank">17267805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31038360">
<a name="31038360"></a>Steingard R, Taskiran S, Connor DF, Markowitz JS, Stein MA. New formulations of stimulants: An update for clinicians. <i>J Child Adolesc Psychopharmacol</i>. 2019;29(5):324-339. doi: 10.1089/cap.2019.0043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/31038360/pubmed" id="31038360" target="_blank">31038360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26608309">
<a name="26608309"></a>Storebø OJ, Krogh HB, Ramstad E, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. <i>BMJ</i>. 2015;351:h5203. doi:10.1136/bmj.h5203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/26608309/pubmed" id="26608309" target="_blank">26608309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29744873">
<a name="29744873"></a>Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. <i>Cochrane Database Syst Rev</i>. 2018;5(5):CD012069. doi:10.1002/14651858.CD012069.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/29744873/pubmed" id="29744873" target="_blank">29744873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22003063">
<a name="22003063"></a>Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2011;128(5):1007-1022. doi:10.1542/peds.2011-2654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22003063/pubmed" id="22003063" target="_blank">22003063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADHD.1">
<a name="ADHD.1"></a>Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, et al. Supplemental information: Implementing the key action statements: An algorithm and explanation for process of care for the evaluation, diagnosis, treatment, and monitoring of ADHD in children and adolescents. <i>Pediatrics</i>. 2011. Available at http://pediatrics.aappublications.org/content/pediatrics/suppl/2011/10/11/peds.2011-2654.DC1/zpe611117822p.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18024065">
<a name="18024065"></a>Thompson J, Thompson JR. Acute myocardial infarction related to methylphenidate for adult attention deficit disorder. <i>J Emerg Med</i>. 2010;38(1):18-21. doi:10.1016/j.jemermed.2007.06.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18024065/pubmed" id="18024065" target="_blank">18024065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23433999">
<a name="23433999"></a>Thorpy M, Zhao CG, and Dauvilliers Y, "Management of Narcolepsy During Pregnancy," <i>Sleep Med</i>, 2013, 14(4):367-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23433999/pubmed" id="23433999" target="_blank">23433999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29790008">
<a name="29790008"></a>Uzun ME, Korkmaz MF, Ekici A, Kaymaz N. Methylphenidate induced acute dystonic reaction. <i>Indian J Pediatr</i>. 2018;85(7):577. doi:10.1007/s12098-018-2711-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/29790008/pubmed" id="29790008" target="_blank">29790008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427125">
<a name="18427125"></a>Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing [published correction appears in <i>Circulation</i>. 2009;120(7):e55-e59]. <i>Circulation</i>. 2008;117(18):2407-2423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18427125/pubmed" id="18427125" target="_blank">18427125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17979580">
<a name="17979580"></a>Vitiello B, Abikoff HB, Chuang SZ, et al. Effectiveness of methylphenidate in the 10-month continuation phase of the preschoolers with attention-deficit/hyperactivity disorder treatment study (PATS). <i>J Child Adolesc Psychopharmacol</i>. 2007;17(5):593-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17979580/pubmed" id="17979580" target="_blank">17979580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12589522">
<a name="12589522"></a>Volkow ND, Wang GJ, Fowler JS, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. <i>Psychopharmacology (Berl)</i>. 2003;166(3):264-270. doi:10.1007/s00213-002-1340-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/12589522/pubmed" id="12589522" target="_blank">12589522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7755127">
<a name="7755127"></a>Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. <i>Am J Psychiatry.</i> 1995;152(6):929-931.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/7755127/pubmed" id="7755127" target="_blank">7755127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31473291">
<a name="31473291"></a>Waxmonsky JG, Pelham WE 3rd, Campa A, et al. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(12):1330-1341. doi:10.1016/j.jaac.2019.08.472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/31473291/pubmed" id="31473291" target="_blank">31473291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22682429">
<a name="22682429"></a>Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. <i>BMC Cardiovasc Disord</i>. 2012;12:41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22682429/pubmed" id="22682429" target="_blank">22682429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31967914">
<a name="31967914"></a>Wigal S, Chappell P, Palumbo D, Lubaczewski S, Ramaker S, Abbas R. Diagnosis and treatment options for preschoolers with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol</i>. 2020;30(2):104-118. doi:10.1089/cap.2019.0116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/31967914/pubmed" id="31967914" target="_blank">31967914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23289899">
<a name="23289899"></a>Wigal SB, Childress AC, Belden HW, et al, "NWP06, an Extended Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared With Placebo in a Laboratory Classroom Study," <i>J Child Adolesc Psychopharmacol</i>, January 5, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23289899/pubmed" id="23289899" target="_blank">23289899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28557548">
<a name="28557548"></a>Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol</i>. 2017;27(8):690-699.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28557548/pubmed" id="28557548" target="_blank">28557548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17028508">
<a name="17028508"></a>Wigal T, Greenhill L, Chuang S, et al, "Safety and Tolerability of Methylphenidate in Preschool Children With ADHD," <i>J Am Acad Child Adolesc Psychiatry</i>, 2006, 45(11):1294-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17028508/pubmed" id="17028508" target="_blank">17028508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29476037">
<a name="29476037"></a>Wiggs KK, Chang Z, Quinn PD, et al. Attention-deficit/hyperactivity disorder medication and seizures. <i>Neurology</i>. 2018;90(13):e1104-e1110. doi: 10.1212/WNL.0000000000005213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/29476037/pubmed" id="29476037" target="_blank">29476037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18087648">
<a name="18087648"></a>Yuan J, Desouza R, Westney OL, Wang R. Insights of priapism mechanism and rationale treatment for recurrent priapism. <i>Asian J Androl</i>. 2008;10(1):88-101. doi:10.1111/j.1745-7262.2008.00314.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18087648/pubmed" id="18087648" target="_blank">18087648</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9638 Version 764.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
